

## Calendar No. 168

119TH CONGRESS  
1ST SESSION**H. R. 5371**

IN THE SENATE OF THE UNITED STATES

SEPTEMBER 19 (legislative day, SEPTEMBER 16), 2025

Received, read twice and ordered placed on the calendar

**AN ACT**

Making continuing appropriations and extensions for fiscal  
year 2026, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Continuing Appropria-  
5 tions and Extensions Act, 2026”.

6 **SEC. 2. TABLE OF CONTENTS.**

7 The table of contents for this Act is as follows:

- Sec. 1. SHORT TITLE.
- Sec. 2. TABLE OF CONTENTS.
- Sec. 3. REFERENCES.

DIVISION A—CONTINUING APPROPRIATIONS ACT, 2026

DIVISION B—MISCELLANEOUS EXTENSIONS

DIVISION C—HEALTH EXTENDERS

Title I—Public Health Extenders  
 Title II—Medicare  
 Title III—Human Services  
 Title IV—Medicaid  
 Title V—Food and Drug Administration  
 Title VI—No Surprises Act Implementation

DIVISION D—DEPARTMENT OF VETERANS AFFAIRS EXTENDERS

Title I—Health Care Matters  
 Title II—Benefits  
 Title III—Housing  
 Title IV—Other Matters

DIVISION E—MISCELLANEOUS

1 **SEC. 3. REFERENCES.**

2       Except as expressly provided otherwise, any reference  
 3 to “this Act” contained in any division of this Act shall  
 4 be treated as referring only to the provisions of that divi-  
 5 sion.

6                   **DIVISION A—CONTINUING**

7                   **APPROPRIATIONS ACT, 2026**

8       The following sums are hereby appropriated, out of  
 9 any money in the Treasury not otherwise appropriated,  
 10 and out of applicable corporate or other revenues, receipts,  
 11 and funds, for the several departments, agencies, corpora-  
 12 tions, and other organizational units of Government for  
 13 fiscal year 2026, and for other purposes, namely:

14       SEC. 101. Such amounts as may be necessary, at a  
 15 rate for operations as provided in the applicable appro-  
 16 priations Acts for fiscal year 2025 and under the authority  
 17 and conditions provided in such Acts, for continuing  
 18 projects or activities (including the costs of direct loans

1 and loan guarantees) that are not otherwise specifically  
2 provided for in this Act, that were conducted in fiscal year  
3 2025, and for which appropriations, funds, or other au-  
4 thority were made available in the Full-Year Continuing  
5 Appropriations Act, 2025 (division A of Public Law 119-  
6 4), except sections 1110, 1113, 1114, and 1207; the pro-  
7 viso in paragraph (4) of section 1602; and sections 1708  
8 and 1808; and except section 11104 shall be applied by  
9 substituting “2020, and 2021” for “and 2020”; and ex-  
10 cept sections 774 and 778 of division B, section 540 of  
11 division C, and sections 110 and 112 of division D of Pub-  
12 lic Law 118-42 as continued in effect by section 1101 of  
13 division A of Public Law 119-4; and except section  
14 7069(b) of division F of Public Law 118-47, as continued  
15 in effect by section 1101 of division A of Public Law 119-  
16 4.

17 SEC. 102. (a) No appropriation or funds made avail-  
18 able or authority granted pursuant to section 101 for the  
19 Department of Defense shall be used for:

20 (1) the new production of items not funded for  
21 production in fiscal year 2025 or prior years;

22 (2) the increase in production rates above those  
23 sustained with fiscal year 2025 funds; or

24 (3) the initiation, resumption, or continuation  
25 of any project, activity, operation, or organization

1 (defined as any project, subproject, activity, budget  
2 activity, program element, and subprogram within a  
3 program element, and for any investment items de-  
4 fined as a P–1 line item in a budget activity within  
5 an appropriation account and an R–1 line item that  
6 includes a program element and subprogram element  
7 within an appropriation account) for which appro-  
8 priations, funds, or other authority were not avail-  
9 able during fiscal year 2025.

10 (b) No appropriation or funds made available or au-  
11 thority granted pursuant to section 101 for the Depart-  
12 ment of Defense shall be used to initiate multi-year pro-  
13 curements utilizing advance procurement funding for eco-  
14 nomic order quantity procurement unless specifically ap-  
15 propriated later.

16 SEC. 103. Appropriations made by section 101 shall  
17 be available to the extent and in the manner that would  
18 be provided by the pertinent appropriations Act.

19 SEC. 104. Except as otherwise provided in section  
20 102, no appropriation or funds made available or author-  
21 ity granted pursuant to section 101 shall be used to ini-  
22 tiate or resume any project or activity for which appro-  
23 priations, funds, or other authority were not available dur-  
24 ing fiscal year 2025.

1       SEC. 105. Appropriations made and authority grant-  
2 ed pursuant to this Act shall cover all obligations or ex-  
3 penditures incurred for any project or activity during the  
4 period for which funds or authority for such project or  
5 activity are available under this Act.

6       SEC. 106. Unless otherwise provided for in this Act  
7 or in the applicable appropriations Act for fiscal year  
8 2026, appropriations and funds made available and au-  
9 thority granted pursuant to this Act shall be available  
10 until whichever of the following first occurs:

11           (1) The enactment into law of an appropriation  
12 for any project or activity provided for in this Act.

13           (2) The enactment into law of the applicable  
14 appropriations Act for fiscal year 2026 without any  
15 provision for such project or activity.

16           (3) November 21, 2025.

17       SEC. 107. Expenditures made pursuant to this Act  
18 shall be charged to the applicable appropriation, fund, or  
19 authorization whenever a bill in which such applicable ap-  
20 propriation, fund, or authorization is contained is enacted  
21 into law.

22       SEC. 108. Appropriations made and funds made  
23 available by or authority granted pursuant to this Act may  
24 be used without regard to the time limitations for submis-  
25 sion and approval of apportionments set forth in section

1 1513 of title 31, United States Code, but nothing in this  
2 Act may be construed to waive any other provision of law  
3 governing the apportionment of funds.

4       SEC. 109. Notwithstanding any other provision of  
5 this Act, except section 106, for those programs that  
6 would otherwise have high initial rates of operation or  
7 complete distribution of appropriations at the beginning  
8 of fiscal year 2026 because of distributions of funding to  
9 States, foreign countries, grantees, or others, such high  
10 initial rates of operation or complete distribution shall not  
11 be made, and no grants shall be awarded for such pro-  
12 grams funded by this Act that would impinge on final  
13 funding prerogatives.

14       SEC. 110. This Act shall be implemented so that only  
15 the most limited funding action of that permitted in the  
16 Act shall be taken in order to provide for continuation of  
17 projects and activities.

18       SEC. 111. (a) For entitlements and other mandatory  
19 payments whose budget authority was provided in an ap-  
20 propriations Act specified in section 101, for expenses au-  
21 thorized under section 324 of title 38, United States Code,  
22 and for activities under the Food and Nutrition Act of  
23 2008, activities shall be continued at the rate to maintain  
24 program levels under current law, under the authority and  
25 conditions provided in the applicable appropriations Act,

1 to be continued through the date specified in section  
2 106(3) of this Act.

3 (b) Notwithstanding section 106, obligations for man-  
4 datory payments due on or about the first day of any  
5 month that begins after October 2025 but not later than  
6 30 days after the date specified in section 106(3) may con-  
7 tinue to be made, and funds shall be available for such  
8 payments.

9 SEC. 112. Amounts made available under section 101  
10 for civilian personnel compensation and benefits in each  
11 department and agency may be apportioned up to the rate  
12 for operations necessary to avoid furloughs within such de-  
13 partment or agency, consistent with the applicable appro-  
14 priations Act for fiscal year 2025, except that such author-  
15 ity provided under this section shall not be used until after  
16 the department or agency has taken all necessary actions  
17 to reduce or defer non-personnel-related administrative ex-  
18 penses.

19 SEC. 113. Funds appropriated by this Act may be  
20 obligated and expended notwithstanding section 10 of  
21 Public Law 91–672 (22 U.S.C. 2412), section 15 of the  
22 State Department Basic Authorities Act of 1956 (22  
23 U.S.C. 2680), section 313 of the Foreign Relations Au-  
24 thorization Act, Fiscal Years 1994 and 1995 (22 U.S.C.

1 6212), and section 504(a)(1) of the National Security Act  
2 of 1947 (50 U.S.C. 3094(a)(1)).

3 SEC. 114. (a)(1) For each amount incorporated by  
4 reference in this Act that was previously designated by the  
5 Congress as an emergency requirement pursuant to sec-  
6 tion 251(b)(2)(A)(i) of the Balanced Budget and Emer-  
7 gency Deficit Control Act of 1985, each provision of law  
8 designating each such amount as an emergency require-  
9 ment pursuant to such section shall not apply.

10 (2) Each amount incorporated by reference in  
11 this Act that was designated by the Congress as an  
12 emergency requirement pursuant to section  
13 251(b)(2)(A)(i) of the Balanced Budget and Emer-  
14 gency Deficit Control Act of 1985 in the following  
15 provisions of law are designated by the Congress as  
16 an emergency requirement pursuant to section  
17 4001(a)(1) of S. Con. Res. 14 (117th Congress), the  
18 concurrent resolution on the budget for fiscal year  
19 2022, and to legislation establishing fiscal year 2026  
20 budget enforcement in the House of Representatives:  
21 section 11206(4) of division A of Public Law 119–  
22 4 and 7068(b) of division F of Public Law 118–47,  
23 as continued in effect by section 1101 of division A  
24 of Public Law 119–4.

1 (b) Each amount incorporated by reference in this  
2 Act that was previously designated by the Congress as  
3 being for disaster relief pursuant to section 251(b)(2)(D)  
4 of the Balanced Budget and Emergency Deficit Control  
5 Act of 1985 is designated by the Congress as being for  
6 disaster relief pursuant to a concurrent resolution on the  
7 budget.

8 (c) Each amount incorporated by reference in this  
9 Act that was previously designated in division B of Public  
10 Law 117–159, division J of Public Law 117–58, or in sec-  
11 tion 443(b) of division G of Public Law 117–328 by the  
12 Congress as an emergency requirement pursuant to a con-  
13 current resolution on the budget shall continue to be treat-  
14 ed as an amount specified in section 103(b) of division  
15 A of Public Law 118–5.

16 SEC. 115. (a) Rescissions or cancellations of discre-  
17 tionary budget authority that continue pursuant to section  
18 101 in Treasury Appropriations Fund Symbols (TAFS)—

19 (1) to which other appropriations are not pro-  
20 vided by this Act, but for which there is a current  
21 applicable TAFS that does receive an appropriation  
22 in this Act; or

23 (2) which are no-year TAFS and receive other  
24 appropriations in this Act,

1 may be continued instead by reducing the rate for oper-  
2 ations otherwise provided by section 101 for such current  
3 applicable TAFS, as long as doing so does not impinge  
4 on the final funding prerogatives of the Congress.

5 (b) Rescissions or cancellations described in sub-  
6 section (a) shall continue in an amount equal to the lesser  
7 of—

8 (1) the amount specified for rescission or can-  
9 cellation in the applicable appropriations Act ref-  
10 erenced in section 101 of this Act; or

11 (2) the amount of balances available, as of Oc-  
12 tober 1, 2025, from the funds specified for rescission  
13 or cancellation in the applicable appropriations Act  
14 referenced in section 101 of this Act.

15 (c) No later than November 7, 2025, the Director of  
16 the Office of Management and Budget shall provide to the  
17 Committees on Appropriations of the House of Represent-  
18 atives and the Senate a comprehensive list of the rescis-  
19 sions or cancellations that will continue pursuant to sec-  
20 tion 101: *Provided*, That the information in such com-  
21 prehensive list shall be periodically updated to reflect any  
22 subsequent changes in the amount of balances available,  
23 as of October 1, 2025, from the funds specified for rescis-  
24 sion or cancellation in the applicable appropriations Act  
25 referenced in section 101, and such updates shall be trans-

1 mitted to the Committees on Appropriations of the House  
2 of Representatives and the Senate upon request.

3 SEC. 116. Amounts made available by section 101 for  
4 “Domestic Food Programs—Food and Nutrition Serv-  
5 ice—Special Supplemental Nutrition Program for Women,  
6 Infants, and Children (WIC)” may be apportioned at the  
7 rate for operations necessary to maintain participation.

8 SEC. 117. Section 260 of the Agricultural Marketing  
9 Act of 1946 (7 U.S.C. 1636i) and section 942 of the Live-  
10 stock Mandatory Reporting Act of 1999 (7 U.S.C. 1635  
11 note; Public Law 106–78) shall be applied by substituting  
12 the date specified in section 106 of this Act for “Sep-  
13 tember 30, 2025”.

14 SEC. 118. Section 8302(b) of the Agricultural Act of  
15 2014 (16 U.S.C. 3851a(b)) shall be applied by sub-  
16 stituting the date specified in section 106 of this Act for  
17 “October 1, 2023”.

18 SEC. 119. (a) Amounts made available by section 101  
19 for “Department of Justice—United States Marshals  
20 Service—Salaries and Expenses” may be apportioned up  
21 to the rate for operations necessary to maintain program  
22 operations.

23 (b) In addition to amounts provided by section 101,  
24 for “Department of Justice—United States Marshals  
25 Service—Salaries and Expenses”, there is appropriated

1 \$30,000,000, for an additional amount for fiscal year  
2 2026, to remain available until September 30, 2027, to  
3 carry out protective operations.

4 SEC. 120. (a) For the closeout of all Space Shuttle  
5 contracts and associated programs, amounts that have ex-  
6 pired but have not been cancelled in the Exploration,  
7 Space Operations, Human Space Flight, Space Flight Ca-  
8 pabilities, and Exploration Capabilities appropriations ac-  
9 counts shall remain available through fiscal year 2030 for  
10 the liquidation of valid obligations incurred during the pe-  
11 riod of fiscal year 2001 through fiscal year 2013.

12 (b)(1) Subject to paragraph (2), this section shall be-  
13 come effective immediately upon enactment of this Act.

14 (2) If this Act is enacted after September 30,  
15 2025, this section shall be applied as if it were in  
16 effect on September 30, 2025.

17 SEC. 121. Section 3014(a) of title 18, United States  
18 Code, shall be applied by substituting the date specified  
19 in section 106 of this Act for “September 30, 2025”.

20 SEC. 122. Notwithstanding section 101, the first pro-  
21 viso in each of sections 8092 and 8096 of title VIII of  
22 division A of Public Law 118–47 shall be applied by sub-  
23 stituting “advances” for “reimbursements”.

24 SEC. 123. Notwithstanding sections 102 and 104,  
25 amounts made available by section 101 to the Department

1 of Defense for “Research, Development, Test and Evalua-  
2 tion, Air Force” shall be apportioned up to the rate for  
3 operations necessary for the E-7 Wedgetail program, in  
4 an amount not to exceed \$199,676,000, only for the pur-  
5 pose of continued rapid prototyping activities to maintain  
6 program schedule and transition to production for the E-  
7 7 Wedgetail program.

8       SEC. 124. Of the unobligated balance of funds avail-  
9 able to the Department of Defense for the E-7 program  
10 under the heading “Aircraft Procurement, Air Force” in  
11 Public Law 119-4, \$200,000,000 is hereby transferred to  
12 and merged with amounts available for the E-7 program  
13 under the heading “Research, Development, Test and  
14 Evaluation, Air Force” only for the purpose of continued  
15 rapid prototyping activities to maintain program schedule  
16 and transition to production for the E-7 Wedgetail pro-  
17 gram.

18       SEC. 125. Section 717(a) of the Defense Production  
19 Act of 1950 (50 U.S.C. 4564(a)) shall be applied by sub-  
20 stituting the date specified in section 106 of this Act for  
21 “September 30, 2025”.

22       SEC. 126. Notwithstanding sections 102 and 104,  
23 amounts made available by section 101 of this Act to the  
24 Department of Defense for “Shipbuilding and Conversion,  
25 Navy” may be apportioned up to the rate for operations

1 necessary to fund completion of prior year shipbuilding  
2 programs for the fiscal year 2016 and fiscal year 2018  
3 Virginia Class Submarine Programs, in an amount not to  
4 exceed \$154,000,000.

5       SEC. 127. During the period covered by this Act, sec-  
6 tion 103(f)(4)(A) of Public Law 108–361 (the Calfed Bay-  
7 Delta Authorization Act) shall be applied by substituting  
8 “\$32,600,000” for “\$30,000,000”.

9       SEC. 128. (a) Amounts made available by section 101  
10 in the first proviso under the heading “Department of En-  
11 ergy—Atomic Energy Defense Activities—National Nu-  
12 clear Security Administration—Weapons Activities” may  
13 be apportioned up to the rate for operations necessary to  
14 maintain current operations for the safe, secure transport  
15 of nuclear weapons.

16       (b) The Director of the Office of Management and  
17 Budget and the Secretary of Energy shall notify the Com-  
18 mittees on Appropriations of the House of Representatives  
19 and the Senate not later than 3 days after each use of  
20 the authority provided in subsection (a).

21       SEC. 129. Notwithstanding section 101, the matter  
22 preceding the first proviso under the heading “Office of  
23 Personnel Management—Salaries and Expenses” in title  
24 V of division B of Public Law 118–47 shall be applied  
25 by substituting “\$197,446,000” for “\$219,076,000”, and

1 the second proviso under such heading in such title of such  
2 division of such Act shall be applied by substituting  
3 “\$214,605,000” for “\$192,975,000”.

4 SEC. 130. Notwithstanding any other provision of  
5 this Act, except section 106, the District of Columbia may  
6 expend local funds made available under the heading “Dis-  
7 trict of Columbia—District of Columbia Funds” for such  
8 programs and activities under the District of Columbia  
9 Appropriations Act, 2024 (title IV of division B of Public  
10 Law 118–47) at the rate set forth in the Fiscal Year 2026  
11 Local Budget Act of 2025 (D.C. Bill No. 26–260) as  
12 modified as of the date of enactment of this Act.

13 SEC. 131. Notwithstanding section 101, paragraph  
14 (1) under the heading “Department of the Treasury—De-  
15 partmental Offices—Salaries and Expenses” in title I of  
16 division B of Public Law 118–47 shall be applied by sub-  
17 stituting “\$1,350,000” for “\$350,000”: *Provided*, That  
18 such amounts may be obligated in the account and budget  
19 structure set forth in the fiscal year 2026 President’s  
20 Budget, submitted pursuant to section 1105(a) of title 31,  
21 United States Code, and accompanying justification mate-  
22 rials.

23 SEC. 132. Amounts made available by section 101 for  
24 “Small Business Administration—Business Loans Pro-  
25 gram Account” may be apportioned up to the rate for op-

1 erations necessary to accommodate increased demand for  
2 commitments for general business loans authorized under  
3 paragraphs (1) through (35) of section 7(a) of the Small  
4 Business Act (15 U.S.C. 636(a)), for commitments to  
5 guarantee trust certificates authorized by section 5(g) of  
6 the Small Business Act (15 U.S.C. 634(g)), for commit-  
7 ments to guarantee loans under section 503 of the Small  
8 Business Investment Act of 1958 (15 U.S.C. 697), and  
9 for commitments to guarantee debentures under section  
10 303(b) of the Small Business Investment Act of 1958 (15  
11 U.S.C. 683(b)).

12       SEC. 133. Notwithstanding section 101, amounts are  
13 provided for “Department of the Treasury—Office of Ter-  
14 rorism and Financial Intelligence—Salaries and Ex-  
15 penses” at a rate for operations of \$237,662,000.

16       SEC. 134. Notwithstanding section 101, section 1605  
17 of Public Law 119–4 shall be applied by substituting  
18 “through the end of the last applicable pay period that  
19 commences on or before the date specified in section  
20 106(3) of the Continuing Appropriations Act, 2026” for  
21 “through the date specified in section 1106 of this Act”.

22       SEC. 135. Section 1(b) of Public Law 117–25 (135  
23 Stat. 297; 136 Stat. 2133; 136 Stat. 5984; 138 Stat.  
24 1771; 139 Stat. 46) shall be applied in each of paragraphs

1 (3) and (4) by substituting the date specified in section  
2 106 of this Act for “September 30, 2025”.

3       SEC. 136. In addition to amounts otherwise provided  
4 by section 101 for “The Judiciary—Supreme Court of the  
5 United States—Salaries and Expenses”, there is appro-  
6 priated \$28,000,000, for an additional amount for fiscal  
7 year 2026, to remain available until expended, for the pro-  
8 tection of the Supreme Court Justices, including the pur-  
9 chase and hire of passenger motor vehicles as authorized  
10 by 31 U.S.C. 1343 and 1344, to be expended as the Chief  
11 Justice may approve.

12       SEC. 137. Section 210G(i) of the Homeland Security  
13 Act of 2002 (6 U.S.C. 124n(i)) shall be applied by sub-  
14 stituting the date specified in section 106 of this Act for  
15 “September 30, 2025”.

16       SEC. 138. Section 225(e) of division A of Public Law  
17 116–6 (49 U.S.C. 44901 note) shall be applied by sub-  
18 stituting “fiscal year 2019 through the date specified in  
19 section 106 of the Continuing Appropriations Act, 2026”  
20 for “fiscal years 2019 through 2025”.

21       SEC. 139. Amounts made available by section 101 to  
22 the Department of Homeland Security under the heading  
23 “Federal Emergency Management Agency—Disaster Re-  
24 lief Fund” may be apportioned up to the rate for oper-  
25 ations necessary to carry out response and recovery activi-

1 ties under the Robert T. Stafford Disaster Relief and  
2 Emergency Assistance Act (42 U.S.C. 5121 et seq.).

3 SEC. 140. Section 227(a) of the Federal Cybersecu-  
4 rity Enhancement Act of 2015 (6 U.S.C. 1525(a)) shall  
5 be applied by substituting the date specified in section 106  
6 of this Act for “September 30, 2025”.

7 SEC. 141. Section 111(a) of the Cybersecurity Infor-  
8 mation Sharing Act of 2015 (6 U.S.C. 1510(a)) shall be  
9 applied by substituting the date specified in section 106  
10 of this Act for “September 30, 2025”.

11 SEC. 142. Section 2220A(s)(1) of the Homeland Se-  
12 curity Act of 2002 (6 U.S.C. 665g(s)(1)) shall be applied  
13 by substituting the date specified in section 106 of this  
14 Act for “September 30, 2025”.

15 SEC. 143. During the period covered by this Act, sec-  
16 tion 3(b)(2)(C) of the Pittman-Robertson Wildlife Res-  
17 toration Act (16 U.S.C. 669b(b)(2)(C)) shall be applied  
18 by substituting “2027” for “2026”.

19 SEC. 144. During the period covered by this Act, sec-  
20 tion 1701 of title VII of division B of Public Law 117–  
21 43, as amended, shall be applied by substituting “calendar  
22 years 2021 through 2026” for “2021 or 2022 or 2023  
23 or 2024” each place it appears.

24 SEC. 145. Amounts made available by section 101 for  
25 “Department of the Interior—Department-Wide Pro-

1 grams—Wildland Fire Management” and “Department of  
2 Agriculture—Forest Service—Wildland Fire Manage-  
3 ment” may be apportioned up to the rate for operations  
4 necessary for wildfire suppression activities.

5       SEC. 146. (a) In addition to amounts otherwise pro-  
6 vided by section 101, amounts are provided for “Depart-  
7 ment of Health and Human Services—Indian Health  
8 Service—Indian Health Services” at a rate for operations  
9 of \$72,265,000, for an additional amount for costs of  
10 staffing and operating facilities that were opened, ren-  
11 ovated, or expanded in fiscal years 2025 and 2026, and  
12 such amounts may be apportioned up to the rate for oper-  
13 ations necessary to staff and operate such facilities.

14       (b) In addition to amounts otherwise provided by sec-  
15 tion 101, amounts are provided for “Department of  
16 Health and Human Services—Indian Health Service—In-  
17 dian Health Facilities” at a rate for operations of  
18 \$8,050,000, for an additional amount for costs of staffing  
19 and operating facilities that were opened, renovated, or ex-  
20 panded in fiscal years 2025 and 2026, and such amounts  
21 may be apportioned up to the rate for operations necessary  
22 to staff and operate such facilities.

23       SEC. 147. Of the amounts made available in the third  
24 paragraph under the heading “Environmental Protection  
25 Agency—State and Tribal Assistance Grants” in the Dis-

1 aster Relief Supplemental Appropriations Act, 2023 (divi-  
2 sion N of Public Law 117–328), up to \$54,000,000 shall  
3 be available for technical assistance and grants under sec-  
4 tion 1442(b) of the Safe Drinking Water Act (42 U.S.C.  
5 300j–1(b)) in areas where the President declared an emer-  
6 gency in August of fiscal year 2022 pursuant to the Rob-  
7 ert T. Stafford Disaster Relief and Emergency Assistance  
8 Act (42 U.S.C. 5121 et seq.): *Provided*, That amounts  
9 repurposed pursuant to this section that were previously  
10 designated by the Congress as being for an emergency re-  
11 quirement pursuant to section 4001(a)(1) of S. Con. Res  
12 14 (117th Congress), the concurrent resolution on the  
13 budget for fiscal year 2022, and section 1(e) of H. Res.  
14 1151 (117th Congress), as engrossed in the House of Rep-  
15 resentatives on June 8, 2022, are designated as being for  
16 an emergency requirement pursuant to section 4001(a)(1)  
17 of S. Con. Res. 14 (117th Congress), the concurrent reso-  
18 lution on the budget for fiscal year 2022, and to legislation  
19 establishing fiscal year 2026 budget enforcement in the  
20 House of Representatives.

21 SEC. 148. Notwithstanding section 101, the matter  
22 under the heading “Department of Health and Human  
23 Services—Administration for Children and Families—  
24 Children and Families Services Programs” in title II of  
25 division D of Public Law 118–47 shall be applied by add-

1 ing the following after the second proviso: “*Provided fur-*  
2 *ther*, That for purposes of section 640(a)(2)(B)(v) of such  
3 Act, the base grant for each of the Federated States of  
4 Micronesia and the Republic of the Marshall Islands shall  
5 be \$8,000,000, and shall be considered equal to the  
6 amount provided for base grants for such jurisdictions  
7 under such Act for the prior fiscal year:”.

8 SEC. 149. Notwithstanding any other provision of  
9 this Act, there is appropriated—

10 (1) For payment to Ashley Paige Turner, heir  
11 of Sylvester Turner, late a Representative from the  
12 State of Texas, \$174,000.

13 (2) For payment to Ramona Grijalva, widow of  
14 Raúl M. Grijalva, late a Representative from the  
15 State of Arizona, \$174,000.

16 (3) For payment to Catherine M. Smith, widow  
17 of Gerald E. Connolly, late a Representative from  
18 the Commonwealth of Virginia, \$174,000.

19 SEC. 150. Notwithstanding any other provision of  
20 law, no adjustment shall be made under section 601(a)  
21 of the Legislative Reorganization Act of 1946 (2 U.S.C.  
22 4501) (relating to cost of living adjustments for Members  
23 of Congress) during the period covered by this Act.

24 SEC. 151. In addition to amounts otherwise provided  
25 by section 101, for “Capitol Police—United States Capitol

1 Police Mutual Aid Reimbursements”, there is appro-  
2 priated \$30,000,000, for an additional amount for fiscal  
3 year 2026, to remain available until expended, for reim-  
4 bursements for mutual aid and related training provided  
5 under the agreements described in section 7302 of Public  
6 Law 108–458: *Provided*, That obligation of the funds made  
7 available in this section in this Act shall be subject to noti-  
8 fication to the Chairmen and Ranking Members of the  
9 Committees on Appropriations of both Houses of Con-  
10 gress, the Senate Committee on Rules and Administration,  
11 and the Committee on House Administration of the  
12 amount and purpose of the expense within 15 days of obli-  
13 gation.

14 SEC. 152. Notwithstanding section 101, the matter  
15 under the heading “Native American Veteran Housing  
16 Loan Program Account” in title II of division A of Public  
17 Law 118–42 shall be applied by adding the following new  
18 paragraph: In addition, for the cost of direct loans,  
19 \$6,865,235, as authorized by subchapter V of chapter 37  
20 of title 38, United States Code: *Provided*, That such costs,  
21 including the cost of modifying such loans, shall be as de-  
22 fined in section 502 of the Congressional Budget Act of  
23 1974: *Provided further*, That funds made available under  
24 this heading are available to subsidize gross obligations

1 for the principal amount of direct loans not to exceed  
2 \$75,000,000.”.

3       SEC. 153. Section 1424(a) of the Better Utilization  
4 of Investments Leading to Development Act of 2018 (22  
5 U.S.C. 9624(a)) shall be applied by substituting the date  
6 specified in section 106 of this Act for “the date that is  
7 7 years after the date of the enactment of this Act”.

8       SEC. 154. Notwithstanding sections 101 and 106,  
9 and sections 1101, 1106, and 11201 of Public Law 119–  
10 4, the fifth and sixth provisos under the heading “Millen-  
11 nium Challenge Corporation” in title III of division F of  
12 Public Law 118–47 shall be amended by substituting “De-  
13 cember 31, 2026” for “December 31, 2024” each place  
14 it appears.

15       SEC. 155. Notwithstanding section 106, during fiscal  
16 year 2026, the Secretary of Housing and Urban Develop-  
17 ment may use the unobligated balances of amounts made  
18 available in prior fiscal years in paragraphs (2), (3), and  
19 (8) under the heading “Public and Indian Housing—Ten-  
20 ant-Based Rental Assistance” to support additional alloca-  
21 tions under subparagraph (D) of paragraph (1) and sub-  
22 paragraph (B) of paragraph (4) of such heading to pre-  
23 vent the termination of rental assistance for families as  
24 the result of insufficient funding in the calendar year 2025  
25 funding cycle: *Provided*, That amounts repurposed pursu-

1 ant to this section that were previously designated by the  
2 Congress as an emergency requirement pursuant to a con-  
3 current resolution on the budget or the Balanced Budget  
4 and Emergency Deficit Control Act of 1985 are des-  
5 ignated by the Congress as being for an emergency re-  
6 quirement pursuant to section 4001(a)(1) of S. Con. Res.  
7 14 (117th Congress), the concurrent resolution on the  
8 budget for fiscal year 2022, and to legislation establishing  
9 fiscal year 2026 budget enforcement in the House of Rep-  
10 resentatives.

11 SEC. 156. Amounts made available by section 101 for  
12 “Department of Transportation—Office of the Sec-  
13 retary—Payments to Air Carriers” may be apportioned up  
14 to the rate for operations necessary to maintain Essential  
15 Air Service program operations.

16 SEC. 157. Section 4144(d) of the Motor Carrier Safe-  
17 ty Reauthorization Act of 2005 (49 U.S.C. 31100 note)  
18 shall be applied by substituting the date specified in sec-  
19 tion 106 of this Act for “September 30, 2025”.

20 This division may be cited as the “Continuing Appro-  
21 priations Act, 2026”.

1     **DIVISION B—MISCELLANEOUS**  
2                     **EXTENSIONS**

3     **SEC. 101. UNITED STATES GRAIN STANDARDS.**

4             The authorities (including any limitations on the au-  
5 thorities) provided by each provision of the United States  
6 Grain Standards Act (Public Law 90–487; 7 U.S.C. 74  
7 et seq.) and each provision of law amended by that Act,  
8 as in effect on September 30, 2025, shall continue, and  
9 the authorities (and any such limitations) shall be carried  
10 out, until the later of—

11                 (1) November 21, 2025; and

12                 (2) the date specified in the provision of that  
13 Act or the provision of law amended by that Act.

14                     **DIVISION C—HEALTH**  
15                     **EXTENDERS**  
16                     **TITLE I—PUBLIC HEALTH**  
17                     **EXTENDERS**

18     **SEC. 101. EXTENSION FOR COMMUNITY HEALTH CENTERS,**  
19                     **NATIONAL HEALTH SERVICE CORPS, AND**  
20                     **TEACHING HEALTH CENTERS THAT OPERATE**  
21                     **GME PROGRAMS.**

22             (a) EXTENSION FOR COMMUNITY HEALTH CEN-  
23 TERS.—Section 10503(b)(1) of the Patient Protection and  
24 Affordable Care Act (42 U.S.C. 254b–2(b)(1)) is amend-  
25 ed—

1           (1) in subparagraph (I), by striking “and” at  
2           the end; and

3           (2) by adding at the end the following:

4                   “(K) \$606,904,110 for the period begin-  
5                   ning on October 1, 2025, and ending on No-  
6                   vember 21, 2025; and”.

7           (b) EXTENSION FOR THE NATIONAL HEALTH SERV-  
8           ICE CORPS.—Section 10503(b)(2) of the Patient Protec-  
9           tion and Affordable Care Act (42 U.S.C. 254b–2(b)(2))  
10          is amended—

11           (1) in subparagraph (J), by striking “and” at  
12           the end;

13           (2) in subparagraph (K), by striking the period  
14           at the end and inserting “; and”; and

15           (3) by adding at the end the following:

16                   “(L) \$49,150,685 for the period beginning  
17                   on October 1, 2025, and ending on November  
18                   21, 2025.”.

19           (c) TEACHING HEALTH CENTERS THAT OPERATE  
20           GRADUATE MEDICAL EDUCATION PROGRAMS.—Section  
21           340H(g)(1) of the Public Health Service Act (42 U.S.C.  
22           256h(g)(1)) is amended—

23           (1) in subparagraph (E), by striking “and” at  
24           the end;

1           (2) in subparagraph (F), by striking the period  
2           at the end and inserting “; and”; and

3           (3) by adding at the end the following:

4                   “(G) \$24,931,507 for the period beginning  
5                   on October 1, 2025, and ending on November  
6                   21, 2025.”.

7           (d) APPLICATION OF PROVISIONS.—Amounts appro-  
8           priated pursuant to the amendments made by this section  
9           shall be subject to the requirements contained in Public  
10          Law 117–328 for funds for programs authorized under  
11          sections 330 through 340 of the Public Health Service Act  
12          (42 U.S.C. 254b et seq.).

13          (e) CONFORMING AMENDMENT.—Section 3014(h)(4)  
14          of title 18, United States Code, is amended by striking  
15          “and section 2101(d) of division B of the Full-Year Con-  
16          tinuing Appropriations and Extensions Act, 2025” and in-  
17          serting “section 2101(d) of division B of the Full-Year  
18          Continuing Appropriations and Extensions Act, 2025, and  
19          section 101(d) of title I of division C of the Continuing  
20          Appropriations and Extensions Act, 2026”.

21          **SEC. 102. EXTENSION OF SPECIAL DIABETES PROGRAMS.**

22          (a) EXTENSION OF SPECIAL DIABETES PROGRAMS  
23          FOR TYPE I DIABETES.—Section 330B(b)(2) of the Pub-  
24          lic Health Service Act (42 U.S.C. 254c–2(b)(2)) is amend-  
25          ed—

1 (1) in subparagraph (F), by striking “and” at  
2 the end;

3 (2) in subparagraph (G), by striking the period  
4 at the end and inserting “; and”; and

5 (3) by adding at the end the following:

6 “(H) \$22,652,055 for the period beginning  
7 on October 1, 2025, and ending on November  
8 21, 2025, to remain available until expended.”.

9 (b) **EXTENDING FUNDING FOR SPECIAL DIABETES**  
10 **PROGRAMS FOR INDIANS.**—Section 330C(c)(2) of the  
11 Public Health Service Act (42 U.S.C. 254c–3(c)(2)) is  
12 amended—

13 (1) in subparagraph (F), by striking “and” at  
14 the end;

15 (2) in subparagraph (G), by striking the period  
16 at the end and inserting “; and”; and

17 (3) by adding at the end the following:

18 “(H) \$22,652,055 for the period beginning  
19 on October 1, 2025, and ending on November  
20 21, 2025, to remain available until expended.”.

21 **SEC. 103. NATIONAL HEALTH SECURITY EXTENSIONS.**

22 (a) Section 319(e)(8) of the Public Health Service  
23 Act (42 U.S.C. 247d(e)(8)) is amended by striking “Sep-  
24 tember 30, 2025” and inserting “November 21, 2025”.

1 (b) Section 319L(e)(1)(D) of the Public Health Serv-  
2 ice Act (42 U.S.C. 247d–7e(e)(1)(D)) is amended by strik-  
3 ing “September 30, 2025” and inserting “November 21,  
4 2025”.

5 (c) Section 319L–1(b) of the Public Health Service  
6 Act (42 U.S.C. 247d–7f(b)) is amended by striking “Sep-  
7 tember 30, 2025” and inserting “November 21, 2025”.

8 (d)(1) Section 2811A(g) of the Public Health Service  
9 Act (42 U.S.C. 300hh–10b(g)) is amended by striking  
10 “September 30, 2025” and inserting “November 21,  
11 2025”.

12 (2) Section 2811B(g)(1) of the Public Health Service  
13 Act (42 U.S.C. 300hh–10c(g)(1)) is amended by striking  
14 “September 30, 2025” and inserting “November 21,  
15 2025”.

16 (3) Section 2811C(g)(1) of the Public Health Service  
17 Act (42 U.S.C. 300hh–10d(g)(1)) is amended by striking  
18 “September 30, 2025” and inserting “November 21,  
19 2025”.

20 (e) Section 2812(c)(4)(B) of the Public Health Serv-  
21 ice Act (42 U.S.C. 300hh–11(c)(4)(B)) is amended by  
22 striking “September 30, 2025” and inserting “November  
23 21, 2025”.

## TITLE II—MEDICARE

1  
2 **SEC. 201. EXTENSION OF INCREASED INPATIENT HOSPITAL**  
3 **PAYMENT ADJUSTMENT FOR CERTAIN LOW-**  
4 **VOLUME HOSPITALS.**

5 (a) IN GENERAL.—Section 1886(d)(12) of the Social  
6 Security Act (42 U.S.C. 1395ww(d)(12)) is amended—

7 (1) in subparagraph (B), by striking “in fiscal  
8 year 2026” and inserting “during the portion of fis-  
9 cal year 2026 beginning on November 22, 2025, and  
10 ending on September 30, 2026, and in fiscal year  
11 2027”;

12 (2) in subparagraph (C)(i)—

13 (A) in the matter preceding subclause  
14 (I)—

15 (i) by inserting “or portion of a fiscal  
16 year” after “for a fiscal year”; and

17 (ii) by inserting “and the portion of  
18 fiscal year 2026 beginning on October 1,  
19 2025, and ending on November 21, 2025”  
20 after “through 2025”;

21 (B) in subclause (III), by inserting “and  
22 the portion of fiscal year 2026 beginning on Oc-  
23 tober 1, 2025, and ending on November 21,  
24 2025” after “through 2025”; and

1 (C) in subclause (IV), by striking “fiscal  
2 year 2026” and inserting “the portion of fiscal  
3 year 2026 beginning on November 22, 2025,  
4 and ending on September 30, 2026, and fiscal  
5 year 2027”; and

6 (3) in subparagraph (D)—

7 (A) in the matter preceding clause (i), by  
8 inserting “or during the portion of fiscal year  
9 2026 beginning on October 1, 2025, and ending  
10 on November 21, 2025” after “through 2025”;  
11 and

12 (B) in clause (ii), by inserting “and the  
13 portion of fiscal year 2026 beginning on Octo-  
14 ber 1, 2025, and ending on November 21,  
15 2025” after “through 2025”.

16 (b) IMPLEMENTATION.—Notwithstanding any other  
17 provision of law, the Secretary of Health and Human  
18 Services may implement the amendments made by this  
19 section by program instruction or otherwise.

20 **SEC. 202. EXTENSION OF THE MEDICARE-DEPENDENT HOS-**  
21 **PITAL (MDH) PROGRAM.**

22 (a) IN GENERAL.—Section 1886(d)(5)(G) of the So-  
23 cial Security Act (42 U.S.C. 1395ww(d)(5)(G)) is amend-  
24 ed—

1           (1) in clause (i), by striking “October 1, 2025”  
2           and inserting “November 22, 2025”; and

3           (2) in clause (ii)(II), by striking “October 1,  
4           2025” and inserting “November 22, 2025”.

5           (b) CONFORMING AMENDMENTS.—

6           (1) IN GENERAL.—Section 1886(b)(3)(D) of  
7           the Social Security Act (42 U.S.C.  
8           1395ww(b)(3)(D)) is amended—

9                   (A) in the matter preceding clause (i), by  
10                   striking “October 1, 2025” and inserting “No-  
11                   vember 22, 2025”; and

12                   (B) in clause (iv), by inserting “and the  
13                   portion of fiscal year 2026 beginning on Octo-  
14                   ber 1, 2025, and ending on November 21,  
15                   2025” after “through fiscal year 2025”.

16           (2) PERMITTING HOSPITALS TO DECLINE RE-  
17           CLASSIFICATION.—Section 13501(e)(2) of the Omni-  
18           bus Budget Reconciliation Act of 1993 (42 U.S.C.  
19           1395ww note) is amended by inserting “, or the por-  
20           tion of fiscal year 2026 beginning on October 1,  
21           2025, and ending on November 21, 2025” after  
22           “through fiscal year 2025”.

1 **SEC. 203. EXTENSION OF ADD-ON PAYMENTS FOR AMBU-**  
2 **LANCE SERVICES.**

3 Section 1834(l) of the Social Security Act (42 U.S.C.  
4 1395m(l)) is amended—

5 (1) in paragraph (12)(A), by striking “October  
6 1, 2025” and inserting “November 22, 2025”; and

7 (2) in paragraph (13), by striking “October 1,  
8 2025” each place it appears and inserting “Novem-  
9 ber 22, 2025” in each such place.

10 **SEC. 204. EXTENSION OF FUNDING FOR QUALITY MEASURE**  
11 **ENDORSEMENT, INPUT, AND SELECTION.**

12 Section 1890(d)(2) of the Social Security Act (42  
13 U.S.C. 1395aaa(d)(2)) is amended—

14 (1) in the first sentence, by striking “Sep-  
15 tember 30, 2025” and inserting “November 21,  
16 2025”; and

17 (2) in the third sentence, by striking “Sep-  
18 tember 30, 2025” and inserting “November 21,  
19 2025”.

20 **SEC. 205. EXTENSION OF FUNDING OUTREACH AND ASSIST-**  
21 **ANCE FOR LOW-INCOME PROGRAMS.**

22 (a) STATE HEALTH INSURANCE ASSISTANCE PRO-  
23 GRAMS.—Subsection (a)(1)(B)(xiv) of section 119 of the  
24 Medicare Improvements for Patients and Providers Act of  
25 2008 (42 U.S.C. 1395b–3 note) is amended by striking

1 “September 30, 2025, \$30,000,000” and inserting “No-  
2 vember 21, 2025, \$32,136,986”.

3 (b) AREA AGENCIES ON AGING.—Subsection  
4 (b)(1)(B)(xiv) of such section 119 is amended by striking  
5 “September 30, 2025, \$30,000,000” and inserting “No-  
6 vember 21, 2025, \$32,136,986”.

7 (c) AGING AND DISABILITY RESOURCE CENTERS.—  
8 Subsection (c)(1)(B)(xiv) of such section 119 is amended  
9 by striking “September 30, 2025, \$10,000,000” and in-  
10 serting “November 21, 2025, \$10,712,329”.

11 (d) COORDINATION OF EFFORTS TO INFORM OLDER  
12 AMERICANS ABOUT BENEFITS AVAILABLE UNDER FED-  
13 ERAL AND STATE PROGRAMS.—Subsection (d)(2)(xiv) of  
14 such section 119 is amended by striking “September 30,  
15 2025, \$30,000,000” and inserting “November 21, 2025,  
16 \$32,136,986”.

17 **SEC. 206. EXTENSION OF THE WORK GEOGRAPHIC INDEX**  
18 **FLOOR.**

19 Section 1848(e)(1)(E) of the Social Security Act (42  
20 U.S.C. 1395w–4(e)(1)(E)) is amended by striking “Octo-  
21 ber 1, 2025” and inserting “November 22, 2025”.

22 **SEC. 207. EXTENSION OF CERTAIN TELEHEALTH FLEXIBILI-**  
23 **TIES.**

24 (a) REMOVING GEOGRAPHIC REQUIREMENTS AND  
25 EXPANDING ORIGINATING SITES FOR TELEHEALTH

1 SERVICES.—Section 1834(m) of the Social Security Act  
2 (42 U.S.C. 1395m(m)) is amended—

3 (1) in paragraph (2)(B)(iii), by striking “end-  
4 ing September 30, 2025” and inserting “ending No-  
5 vember 21, 2025”; and

6 (2) in paragraph (4)(C)(iii), by striking “ending  
7 on September 30, 2025” and inserting “ending on  
8 November 21, 2025”.

9 (b) EXPANDING PRACTITIONERS ELIGIBLE TO FUR-  
10 NISH TELEHEALTH SERVICES.—Section 1834(m)(4)(E)  
11 of the Social Security Act (42 U.S.C. 1395m(m)(4)(E))  
12 is amended by striking “ending on September 30, 2025”  
13 and inserting “ending on November 21, 2025”.

14 (c) EXTENDING TELEHEALTH SERVICES FOR FED-  
15 ERALLY QUALIFIED HEALTH CENTERS AND RURAL  
16 HEALTH CLINICS.—Section 1834(m)(8)(A) of the Social  
17 Security Act (42 U.S.C. 1395m(m)(8)(A)) is amended by  
18 striking “ending on September 30, 2025” and inserting  
19 “ending on November 21, 2025”.

20 (d) DELAYING THE IN-PERSON REQUIREMENTS  
21 UNDER MEDICARE FOR MENTAL HEALTH SERVICES  
22 FURNISHED THROUGH TELEHEALTH AND TELE-  
23 COMMUNICATIONS TECHNOLOGY.—

24 (1) DELAY IN REQUIREMENTS FOR MENTAL  
25 HEALTH SERVICES FURNISHED THROUGH TELE-

1 HEALTH.—Section 1834(m)(7)(B)(i) of the Social  
2 Security Act (42 U.S.C. 1395m(m)(7)(B)(i)) is  
3 amended, in the matter preceding subclause (I), by  
4 striking “on or after October 1, 2025” and inserting  
5 “on or after November 22, 2025”.

6 (2) MENTAL HEALTH VISITS FURNISHED BY  
7 RURAL HEALTH CLINICS.—Section 1834(y)(2) of the  
8 Social Security Act (42 U.S.C. 1395m(y)(2)) is  
9 amended by striking “October 1, 2025” and insert-  
10 ing “November 22, 2025”.

11 (3) MENTAL HEALTH VISITS FURNISHED BY  
12 FEDERALLY QUALIFIED HEALTH CENTERS.—Section  
13 1834(o)(4)(B) of the Social Security Act (42 U.S.C.  
14 1395m(o)(4)(B)) is amended by striking “October 1,  
15 2025” and inserting “November 22, 2025”.

16 (e) ALLOWING FOR THE FURNISHING OF AUDIO-  
17 ONLY TELEHEALTH SERVICES.—Section 1834(m)(9) of  
18 the Social Security Act (42 U.S.C. 1395m(m)(9)) is  
19 amended by striking “ending on September 30, 2025” and  
20 inserting “ending on November 21, 2025”.

21 (f) EXTENDING USE OF TELEHEALTH TO CONDUCT  
22 FACE-TO-FACE ENCOUNTER PRIOR TO RECERTIFICATION  
23 OF ELIGIBILITY FOR HOSPICE CARE.—Section  
24 1814(a)(7)(D)(i)(II) of the Social Security Act (42 U.S.C.  
25 1395f(a)(7)(D)(i)(II)) is amended by striking “ending on

1 September 30, 2025” and inserting “ending on November  
2 21, 2025”.

3 (g) PROGRAM INSTRUCTION AUTHORITY.—The Sec-  
4 retary of Health and Human Services may implement the  
5 amendments made by this section through program in-  
6 struction or otherwise.

7 **SEC. 208. EXTENDING ACUTE HOSPITAL CARE AT HOME**  
8 **WAIVER AUTHORITIES.**

9 Section 1866G(a)(1) of the Social Security Act (42  
10 U.S.C. 1395cc–7(a)(1)) is amended by striking “Sep-  
11 tember 30, 2025” and inserting “November 21, 2025”.

12 **SEC. 209. EXTENSION OF TEMPORARY INCLUSION OF AU-**  
13 **THORIZED ORAL ANTIVIRAL DRUGS AS COV-**  
14 **ERED PART D DRUGS.**

15 Section 1860D–2(e)(1)(C) of the Social Security Act  
16 (42 U.S.C. 1395w–102(e)(1)(C)) is amended by striking  
17 “September 30, 2025” and inserting “November 21,  
18 2025”.

19 **SEC. 210. EXTENSION OF FUNDING FOR MEDICARE HOS-**  
20 **PICE SURVEYS.**

21 Section 3(a)(2) of the IMPACT Act of 2014 (Public  
22 Law 113–185) is amended—

23 (1) in subparagraph (A), by striking “and” at  
24 the end;

1           (2) in subparagraph (B), by striking the period  
2           at the end and inserting “; and”; and

3           (3) by adding at the end the following new sub-  
4           paragraph:

5                   “(C) \$6,000,000 for the period beginning  
6                   on October 1, 2025, and ending on November  
7                   21, 2025.”.

8   **SEC. 211. MEDICARE IMPROVEMENT FUND.**

9           Section 1898(b)(1) of the Social Security Act (42  
10   U.S.C. 1395iii(b)(1)) is amended—

11           (1) by striking “fiscal year 2026” and inserting  
12           “fiscal year 2027”; and

13           (2) by striking “\$1,804,000,000” and inserting  
14           “\$664,000,000”.

15   **TITLE III—HUMAN SERVICES**

16   **SEC. 301. SEXUAL RISK AVOIDANCE EDUCATION EXTEN-**  
17           **SION.**

18           Section 510 of the Social Security Act (42 U.S.C.  
19   710) is amended—

20           (1) in subsection (a)—

21                   (A) in paragraph (1)—

22                           (i) by striking “2023, for the period  
23                           beginning on October 1, 2023, and ending  
24                           on November 17, 2023, for the period be-  
25                           ginning on November 18, 2023, and end-

1 ing on January 19, 2024, for the period  
2 beginning on January 20, 2024, and end-  
3 ing on March 8, 2024, for the period be-  
4 ginning on March 9, 2024, and ending on  
5 September 30, 2024, and for fiscal year  
6 2025” and inserting “2025, and for the  
7 period beginning on October 1, 2025, and  
8 ending on November 21, 2025”; and

9 (ii) by striking “fiscal year 2024” and  
10 inserting “fiscal year 2026”; and

11 (B) in paragraph (2)—

12 (i) in subparagraph (A)—

13 (I) by striking “through 2023”  
14 and inserting “through 2025”;

15 (II) by striking “fiscal year 2024  
16 or 2025” and inserting “fiscal year  
17 2026”; and

18 (III) by inserting “(or, with re-  
19 spect to the applicable period, for fis-  
20 cal year 2026)” after “an application  
21 for the fiscal year”; and

22 (ii) in subparagraph (B)(i), by strik-  
23 ing “2024 or 2025” and inserting “2026”;  
24 and

1           (2) in subsection (f)(1) by striking “2023, for  
2           the period beginning on October 1, 2023, and ending  
3           on November 17, 2023, an amount equal to the pro  
4           rata portion of the amount appropriated for the cor-  
5           responding period for fiscal year 2023, for the pe-  
6           riod beginning on November 18, 2023, and ending  
7           on January 19, 2024, an amount equal to the pro  
8           rata portion of the amount appropriated for the cor-  
9           responding period for fiscal year 2023, for the pe-  
10          riod beginning on January 20, 2024, and ending on  
11          March 8, 2024, an amount equal to the pro rata  
12          portion of the amount appropriated for the period at  
13          the end of the corresponding sentence for fiscal year  
14          2023, for the period beginning on March 9, 2024,  
15          and ending on September 30, 2024, an amount  
16          equal to the pro rata portion of the amount appro-  
17          priated for the corresponding period for fiscal year  
18          2023, and for fiscal year 2025, an amount equal to  
19          the amount appropriated for fiscal year 2024” and  
20          inserting “2025, and for the period beginning on Oc-  
21          tober 1, 2025, and ending on November 21, 2025,  
22          an amount equal to the pro rata portion of the  
23          amount appropriated for the corresponding period  
24          for fiscal year 2025”.

1 **SEC. 302. PERSONAL RESPONSIBILITY EDUCATION EXTEN-**  
2 **SION.**

3 Section 513 of the Social Security Act (42 U.S.C.  
4 713) is amended—

5 (1) in subsection (a)(1)—

6 (A) in subparagraph (A), in the matter  
7 preceding clause (i), by striking “2023, for the  
8 period beginning on October 1, 2023, and end-  
9 ing on November 17, 2023, for the period be-  
10 ginning on November 18, 2023, and ending on  
11 January 19, 2024, for the period beginning on  
12 January 20, 2024, and ending on March 8,  
13 2024, for the period beginning on March 9,  
14 2024, and ending on September 30, 2024, and  
15 for fiscal year 2025” and inserting “2025, and  
16 for the period beginning on October 1, 2025,  
17 and ending on November 21, 2025”; and

18 (B) in subparagraph (B)(i), by striking  
19 “the period beginning on October 1, 2023, and  
20 ending on November 17, 2023, for the period  
21 beginning on November 18, 2023, and ending  
22 on January 19, 2024, for the period beginning  
23 on January 20, 2024, and ending on March 8,  
24 2024, for the period beginning on March 9,  
25 2024, and ending on September 30, 2024, and  
26 for fiscal year 2025” and inserting “fiscal years

1           2024 and 2025, and for the period beginning  
2           on October 1, 2025, and ending on November  
3           21, 2025”;

4           (2) in subsection (e)(3), by striking “2024 or  
5           2025” and inserting “2026”; and

6           (3) in subsection (f), by striking “2023, for the  
7           period beginning on October 1, 2023, and ending on  
8           November 17, 2023, an amount equal to the pro  
9           rata portion of the amount appropriated for the cor-  
10          responding period for fiscal year 2023, for the pe-  
11          riod beginning on November 18, 2023, and ending  
12          on January 19, 2024, an amount equal to the pro  
13          rata portion of the amount appropriated for the cor-  
14          responding period for fiscal year 2023, for the pe-  
15          riod beginning on January 20, 2024, and ending on  
16          March 8, 2024, an amount equal to the pro rata  
17          portion of the amount appropriated for the cor-  
18          responding period for fiscal year 2023, for the pe-  
19          riod beginning on March 9, 2024, and ending on  
20          September 30, 2024, an amount equal to the pro  
21          rata portion of the amount appropriated for the cor-  
22          responding period for fiscal year 2023, and for fiscal  
23          year 2025, an amount equal to the amount appro-  
24          priated for fiscal year 2024 for fiscal year 2024”  
25          and inserting “2025, and for the period beginning

1 on October 1, 2025, and ending on November 21,  
2 2025, an amount equal to the pro rata portion of  
3 the amount appropriated for the corresponding pe-  
4 riod for fiscal year 2025”.

5 **SEC. 303. EXTENSION OF FUNDING FOR FAMILY-TO-FAMILY**  
6 **HEALTH INFORMATION CENTERS.**

7 Section 501(c)(1)(A) of the Social Security Act (42  
8 U.S.C. 701(c)(1)(A)) is amended—

9 (1) in clause (vii), by striking “and” at the end;

10 (2) in clause (viii), by adding “; and” at the  
11 end; and

12 (3) by adding at the end the following new  
13 clause:

14 “(ix) \$854,795 for the portion of fiscal year  
15 2026 beginning on October 1, 2025, and ending on  
16 November 21, 2025.”

17 **TITLE IV—MEDICAID**

18 **SEC. 401. MODIFYING CERTAIN DISPROPORTIONATE SHARE**  
19 **HOSPITAL ALLOTMENTS.**

20 (a) **EXTENDING TENNESSEE DSH ALLOTMENTS.—**

21 Section 1923(f)(6)(A)(vi) of the Social Security Act (42  
22 U.S.C. 1396r-4(f)(6)(A)(vi)) is amended—

23 (1) in the heading, by inserting “AND A POR-  
24 TION OF FISCAL YEAR 2026” after “2025”; and

1           (2) by inserting “, and the DSH allotment for  
2           Tennessee for the portion of fiscal year 2026 begin-  
3           ning October 1, 2025, and ending November 21,  
4           2025, shall be \$7,564,932” before the period.

5           (b) DELAYING DSH ALLOTMENT REDUCTIONS.—  
6           Section 1923(f) of the Social Security Act (42 U.S.C.  
7           1396r-4(f)) is amended—

8           (1) in paragraph (7)(A)—

9           (A) in clause (i)—

10           (i) in the matter preceding subclause  
11           (I), by striking “For each of fiscal years  
12           2026 through 2028” and inserting “For  
13           the period beginning November 22, 2025,  
14           and ending September 30, 2026, and for  
15           each of fiscal years 2027 and 2028”;

16           (ii) in subclause (I), by inserting “or  
17           period” after “the fiscal year”; and

18           (iii) in subclause (II), by inserting “or  
19           period” after “in the fiscal year”; and

20           (B) in clause (ii), by striking “for each of  
21           fiscal years 2026 through 2028” and inserting  
22           “for the period beginning November 22, 2025,  
23           and ending September 30, 2026, and for each  
24           of fiscal years 2027 and 2028”; and

1           (2) in paragraph (8), by striking “2027” and  
2           inserting “2028”.

3           **TITLE V—FOOD AND DRUG**  
4           **ADMINISTRATION**

5           **SEC. 501. SHORT TITLE.**

6           This title may be cited as the “Over-the-Counter  
7           Monograph Drug User Fee Amendments”.

8           **SEC. 502. FINDING.**

9           Congress finds that the fees authorized by the  
10          amendments made in this title will be dedicated to over-  
11          the-counter (OTC) monograph drug activities, as set forth  
12          in the goals identified for purposes of part 10 of sub-  
13          chapter C of chapter VII of the Federal Food, Drug, and  
14          Cosmetic Act (21 U.S.C. 379j–71 et seq.), in the letters  
15          from the Secretary of Health and Human Services to the  
16          Chairman of the Committee on Energy and Commerce of  
17          the House of Representatives and the Chairman of the  
18          Committee on Health, Education, Labor, and Pensions of  
19          the Senate, as set forth in the Congressional Record.

20          **SEC. 503. DEFINITIONS.**

21          Section 744L(9)(A) of the Federal Food, Drug, and  
22          Cosmetic Act (21 U.S.C. 379j–71(9)(A)) is amended—

23                  (1) in clause (v), by striking “; or” and insert-  
24                  ing a semicolon;

25                  (2) in clause (vi)—

1 (A) by striking “addition” and inserting  
2 “the addition”; and

3 (B) by striking the period and inserting “;  
4 or”; and

5 (3) by adding at the end the following:

6 “(vii) the addition or modification of a  
7 testing procedure applicable to one or more  
8 OTC monograph drugs, provided that such ad-  
9 ditional or modified testing procedure reflects a  
10 voluntary consensus standard with respect to  
11 pharmaceutical quality that is—

12 “(I) established by a national or inter-  
13 national standards development organiza-  
14 tion; and

15 “(II) recognized by the Secretary  
16 through a process described in guidance  
17 for industry, initially published in July  
18 2023, or any successor guidance, publicly  
19 available on the website of the Food and  
20 Drug Administration, which addresses vol-  
21 untary consensus standards for pharma-  
22 ceutical quality.”.

1 **SEC. 504. AUTHORITY TO ASSESS AND USE OTC MONO-**  
2 **GRAPH FEES.**

3 (a) **TYPES OF FEES.**—Section 744M(a)(1) of the  
4 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–  
5 72(a)(1)) is amended—

6 (1) in subparagraph (A)—

7 (A) by striking “on December 31 of the  
8 fiscal year or at any time during the preceding  
9 12-month period” and inserting “at any time  
10 during the applicable period specified in clause  
11 (ii) for a fiscal year”;

12 (B) by striking “Each person” and insert-  
13 ing the following:

14 “(i) **ASSESSMENT OF FEES.**—Each  
15 person”; and

16 (C) by adding at the end the following:

17 “(ii) **APPLICABLE PERIOD.**—For pur-  
18 poses of clause (i), the applicable period  
19 is—

20 “(I) for fiscal year 2026, the 12-  
21 month period ending on December 31,  
22 2025;

23 “(II) for fiscal year 2027, the 9-  
24 month period ending on September  
25 30, 2026; and

1                   “(III) for fiscal year 2028 and  
2                   each subsequent fiscal year, the 12-  
3                   month period ending on September 30  
4                   of the preceding fiscal year.”;

5                   (2) in subparagraph (B)(i), by amending sub-  
6                   clause (I) to read as follows:

7                   “(I) has ceased all activities re-  
8                   lated to OTC monograph drugs prior  
9                   to—

10                   “(aa) for purposes of fiscal  
11                   year 2026, January 1, 2025;

12                   “(bb) for purposes of fiscal  
13                   year 2027, January 1, 2026; and

14                   “(cc) for purposes of fiscal  
15                   year 2028 and each subsequent  
16                   fiscal year, October 1 of the pre-  
17                   ceding fiscal year; and”;

18                   (3) by amending subparagraph (D) to read as  
19                   follows:

20                   “(D) DUE DATE.—

21                   “(i) FISCAL YEAR 2026.—For fiscal  
22                   year 2026, the facility fees required under  
23                   subparagraph (A) shall be due on the later  
24                   of—

1           “(I) the first business day of  
2           June of such year; or

3           “(II) the first business day after  
4           the enactment of an appropriations  
5           Act providing for the collection and  
6           obligation of fees under this section  
7           for such year.

8           “(ii) FISCAL YEAR 2027.—For fiscal  
9           year 2027, the facility fees required under  
10          subparagraph (A) shall be due—

11           “(I) in a first installment rep-  
12          resenting 50 percent of such fee, on  
13          the later of—

14           “(aa) October 1, 2026; or

15           “(bb) the first business day  
16          after the enactment of an appro-  
17          priations Act providing for the  
18          collection and obligation of fees  
19          under this section for such year;  
20          and

21           “(II) in a second installment rep-  
22          resenting the remaining 50 percent of  
23          such fee, on—

24           “(aa) February 1, 2027; or

1                   “(bb) if an appropriations  
2                   Act described in subclause  
3                   (I)(bb) is not in effect on Feb-  
4                   ruary 1, 2027, the first business  
5                   day after enactment of such an  
6                   appropriations Act.

7                   “(iii) SUBSEQUENT FISCAL YEARS.—  
8                   For fiscal year 2028 and each subsequent  
9                   fiscal year, the facility fees required under  
10                  subparagraph (A) shall be due on the later  
11                  of—

12                   “(I) the first business day on or  
13                   after October 1 of the fiscal year; or

14                   “(II) the first business day after  
15                   the date of enactment of an appro-  
16                   priations Act providing for the collec-  
17                   tion and obligation of fees under this  
18                   section for the fiscal year.”.

19                  (b) FEE REVENUE AMOUNTS.—Section 744M(b) of  
20                  the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
21                  379j–72(b)) is amended to read as follows:

22                  “(b) FEE REVENUE AMOUNTS.—

23                   “(1) IN GENERAL.—For each of the fiscal years  
24                   2026 through 2030, fees under subsection (a)(1)

1 shall be established to generate a total facility fee  
2 revenue amount equal to the sum of—

3 “(A) the annual base revenue for the fiscal  
4 year (as determined under paragraph (2));

5 “(B) the dollar amount equal to the infla-  
6 tion adjustment for the fiscal year (as deter-  
7 mined under subsection (c)(1));

8 “(C) the dollar amount equal to the oper-  
9 ating reserve adjustment for the fiscal year, if  
10 applicable (as determined under subsection  
11 (c)(2));

12 “(D) additional direct cost adjustments (as  
13 determined under subsection (c)(3));

14 “(E) an additional dollar amount equal  
15 to—

16 “(i) \$2,373,000 for fiscal year 2026;

17 “(ii) \$1,233,000 for fiscal year 2027;

18 and

19 “(iii) \$854,000 for fiscal year 2028;

20 and

21 “(F) in the case of a fiscal year for which  
22 the Secretary applies the one-time facility fee  
23 workload adjustment under subsection (c)(4),  
24 the dollar amount equal to such adjustment.

1           “(2) ANNUAL BASE REVENUE.—For purposes  
2 of paragraph (1), the dollar amount of the annual  
3 base revenue for a fiscal year shall be—

4           “(A) for fiscal year 2026, the dollar  
5 amount of the total revenue amount established  
6 for fiscal year 2025 under this subsection as in  
7 effect on the day before the date of enactment  
8 of the Over-the-Counter Monograph Drug User  
9 Fee Amendments, not including any adjust-  
10 ments made for such fiscal year 2025 under  
11 subsection (c)(2), as so in effect; and

12           “(B) for fiscal years 2027 through 2030,  
13 the dollar amount of the total revenue amount  
14 established under this subsection for the pre-  
15 vious fiscal year, not including any adjustments  
16 made for such previous fiscal year under sub-  
17 section (c)(2) or (c)(3).”.

18           (c) ADJUSTMENTS; ANNUAL FEE SETTING.—Section  
19 744M(c) of the Federal Food, Drug, and Cosmetic Act  
20 (21 U.S.C. 379j–72(c)) is amended—

21           (1) in paragraph (1)—

22           (A) in subparagraph (A), in the matter  
23 preceding clause (i)—

24           (i) by striking “subsection (b)(2)(B)”  
25 and inserting “subsection (b)(1)(B)”; and

1 (ii) by striking “fiscal year 2022 and  
2 each subsequent fiscal year” and inserting  
3 “each fiscal year”;

4 (B) in subparagraph (B), by striking “fis-  
5 cal year 2022” and all that follows through the  
6 period at the end and inserting the following:

7 “a fiscal year shall be equal to the product of—

8 “(i) for fiscal year 2026—

9 “(I) the fee for fiscal year 2025  
10 under subsection (a)(2); and

11 “(II) the inflation adjustment  
12 percentage under subparagraph (C);  
13 and

14 “(ii) for each of fiscal years 2027  
15 through 2030—

16 “(I) the applicable fee under sub-  
17 section (a)(2) for the preceding fiscal  
18 year; and

19 “(II) the inflation adjustment  
20 percentage under subparagraph (C).”;  
21 and

22 (C) in subparagraph (C)—

23 (i) in the matter preceding clause (i),  
24 by inserting “the sum of” after “is equal  
25 to”;

- 1 (ii) by striking clause (i);
- 2 (iii) by redesignating subclauses (I)
- 3 and (II) of clause (ii) as clauses (i) and
- 4 (ii), respectively, and adjusting the mar-
- 5 gins accordingly;
- 6 (iv) by striking “(ii) for each of fiscal
- 7 years 2024 and 2025, the sum of—”; and
- 8 (v) in clause (ii), as so redesignated,
- 9 by striking “Washington-Baltimore, DC-
- 10 MD-VA-WV” and inserting “Washington-
- 11 Arlington-Alexandria-DC-VA-MD-WV”;
- 12 (2) in paragraph (2)—
- 13 (A) in subparagraph (A)—
- 14 (i) by striking “fiscal year 2021 and
- 15 subsequent fiscal years” and inserting
- 16 “each fiscal year”;
- 17 (ii) by striking “subsections (b)(1)(B)
- 18 and (b)(2)(C)” and inserting “subsection
- 19 (b)(1)(C)”;
- 20 (iii) by striking “the number of weeks
- 21 specified in subparagraph (B)” and insert-
- 22 ing “10 weeks”;
- 23 (B) by striking subparagraph (B);

1 (C) by redesignating subparagraphs (C)  
2 and (D) as subparagraphs (B) and (C), respec-  
3 tively; and

4 (D) in subparagraph (C), as so redesign-  
5 ated, by striking “paragraph (4) establishing”  
6 and inserting “paragraph (5) publishing”;  
7 (3) in paragraph (3)—

8 (A) in the matter preceding subparagraph  
9 (A), by striking “subsection (b)(2)(D)” and in-  
10 serting “subsection (b)(1)(D)”; and

11 (B) by striking subparagraphs (A) through  
12 (E) and inserting the following:

13 “(A) \$135,000 for fiscal year 2026;

14 “(B) \$300,000 for fiscal year 2027;

15 “(C) \$55,000 for fiscal year 2028;

16 “(D) \$30,000 for fiscal year 2029; and

17 “(E) \$0 for fiscal year 2030.”; and

18 (4) by striking paragraph (4) and inserting the  
19 following:

20 “(4) ONE-TIME FACILITY FEE WORKLOAD AD-  
21 JUSTMENT.—

22 “(A) IN GENERAL.—In addition to the ad-  
23 justments under paragraphs (1), (2), and (3),  
24 the Secretary may further increase the fee reve-  
25 nues and fees through a one-time adjustment

1 made for fiscal year 2028, 2029, or 2030, in  
2 accordance with this paragraph.

3 “(B) ADJUSTMENT DESCRIBED.—

4 “(i) CONDITIONS FOR ADJUST-  
5 MENT.—An adjustment under this para-  
6 graph may be made for a fiscal year only  
7 if—

8 “(I) an adjustment under this  
9 paragraph had not been made for any  
10 prior fiscal year;

11 “(II) the average number of OTC  
12 monograph drug facilities subject to a  
13 facility fee under subsection (a)(1)  
14 over the period of the preceding 3 fis-  
15 cal years exceeds 1,625; and

16 “(III) with respect to facilities  
17 described in subclause (II), the aver-  
18 age number of such facilities (ex-  
19 pressed as a percentage) that ap-  
20 peared on the arrears lists pursuant  
21 to subsection (e)(1)(A)(i) over the pe-  
22 riod of the preceding 3 fiscal years is  
23 less than 30 percent.

1           “(ii) AMOUNT OF ADJUSTMENT.—An  
2 adjustment under this paragraph for a fis-  
3 cal year shall equal the product of—

4           “(I) the total facility revenue  
5 amount determined under subsection  
6 (b) for the fiscal year, exclusive of the  
7 adjustment under this paragraph for  
8 such fiscal year; and

9           “(II) the excess facility percent-  
10 age described in clause (iii).

11           “(iii) EXCESS FACILITY PERCENT-  
12 AGE.—The excess facility percentage de-  
13 scribed in this clause is—

14           “(I) the amount by which the av-  
15 erage number of OTC monograph  
16 drug facilities subject to a facility fee  
17 under subsection (a)(1) over the pre-  
18 ceding 3 fiscal years exceeds 1,625;  
19 divided by

20           “(II) 1,625.

21           “(5) ANNUAL FEE SETTING.—The Secretary  
22 shall, not later than 60 days before the first day of  
23 each fiscal year—

24           “(A) establish for such fiscal year, based  
25 on the revenue amounts under subsection (b)

1 and the adjustments provided under this sub-  
2 section—

3 “(i) OTC monograph drug facility fees  
4 under subsection (a)(1); and

5 “(ii) OTC monograph order request  
6 fees under subsection (a)(2); and

7 “(B) publish such fee revenue amounts, fa-  
8 cility fees, and OTC monograph order request  
9 fees in the Federal Register.”.

10 (d) CREDITING AND AVAILABILITY OF FEES.—Sec-  
11 tion 744M(f) of the Federal Food, Drug, and Cosmetic  
12 Act (21 U.S.C. 379j–72(f)) is amended—

13 (1) in paragraph (2)(D)—

14 (A) in the subparagraph heading, by strik-  
15 ing “IN SUBSEQUENT YEARS”; and

16 (B) by striking “(after fiscal year 2021)”;

17 and

18 (2) in paragraph (3), by striking “2021  
19 through 2025” and inserting “2026 through 2030”.

20 **SEC. 505. REAUTHORIZATION; REPORTING REQUIREMENTS.**

21 (a) PERFORMANCE REPORT.—Section 744N of the  
22 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–  
23 73) is amended—

24 (1) in subsection (a)—

1 (A) by striking “Beginning with fiscal year  
2 2021, and not later than 120 calendar days  
3 after the end of each fiscal year thereafter” and  
4 inserting the following:

5 “(1) IN GENERAL.—Not later than 120 cal-  
6 endar days after the end of each fiscal year”;

7 (B) by striking “section 3861(b) of the  
8 CARES Act” and inserting “section 2 of the  
9 Over-the-Counter Monograph Drug User Fee  
10 Amendments”; and

11 (C) by adding at the end the following:

12 “(2) ADDITIONAL INFORMATION.—Beginning  
13 with fiscal year 2026, the annual report under this  
14 subsection shall include—

15 “(A) the progress of the Food and Drug  
16 Administration in achieving the goals, and fu-  
17 ture plans for meeting the goals, including—

18 “(i) the number of Tier 1 OTC mono-  
19 graph order requests for which a proposed  
20 order was issued, and the number of such  
21 requests for which a final order was issued,  
22 in the previous fiscal year;

23 “(ii) the number of Tier 2 OTC  
24 monograph order requests for which a pro-  
25 posed order was issued, and the number of

1 such requests for which a final order was  
2 issued, in the previous fiscal year;

3 “(iii) the number of specified safety  
4 OTC monograph order requests for which  
5 a proposed order was issued, and the num-  
6 ber of such requests for which a final order  
7 was issued, in the previous fiscal year;

8 “(iv) the number of generally recog-  
9 nized as safe and effective finalization  
10 OTC monograph order requests for which  
11 a proposed order was issued, and the num-  
12 ber of such requests for which a final order  
13 was issued, in the previous fiscal year;

14 “(v) the average timeline for proc-  
15 essing OTC monograph order requests, in  
16 the aggregate and by submission type, in  
17 the previous fiscal year; and

18 “(vi) postmarket safety activities with  
19 respect to OTC monograph drugs, includ-  
20 ing—

21 “(I) collecting, developing, and  
22 reviewing safety information on OTC  
23 monograph drugs, including adverse  
24 event reports;

1                   “(II) developing and using im-  
2                   proved analytical tools, adverse event  
3                   data-collection systems, including in-  
4                   formation technology systems, to as-  
5                   sess potential safety problems, includ-  
6                   ing access to external databases; and

7                   “(III) activities under section  
8                   760;

9                   “(B) information regarding registration of  
10                  OTC monograph drug facilities and contract  
11                  manufacturing organization facilities and pay-  
12                  ment of registration fees by such facilities, in-  
13                  cluding—

14                   “(i) the OTC monograph drug facili-  
15                   ties and contract manufacturing organiza-  
16                   tion facilities that were first registered  
17                   under section 510(c) or 510(i) in the fiscal  
18                   year; and

19                   “(ii) for each OTC monograph drug  
20                   facility and contract manufacturing organi-  
21                   zation facility that was assessed a facility  
22                   fee under section 744M(a) in the fiscal  
23                   year, whether the facility paid such fee;

24                   “(C) the status of implementation of evi-  
25                  dence and testing standards under section

1           505G(r) for nonprescription drugs intended for  
2           topical administration, including—

3                   “(i) the application of evidence or  
4                   testing standards; and

5                   “(ii) the number of active ingredient  
6                   requests for nonprescription drugs in-  
7                   tended for topical administration reviewed  
8                   using the standards under section  
9                   505G(b); and

10                   “(D) the progress of the Food and Drug  
11                   Administration in allowing nonclinical testing  
12                   alternatives to animal testing for the consider-  
13                   ation of sunscreen active ingredients.

14                   “(3) CONFIDENTIALITY.—Nothing in para-  
15                   graph (2) shall be construed to authorize the disclo-  
16                   sure of information that is prohibited from disclo-  
17                   sure under section 301(j) of this Act or section 1905  
18                   of title 18, United States Code, or that is subject to  
19                   withholding under section 552(b)(4) of title 5,  
20                   United States Code.”;

21                   (2) in subsection (b), by striking “fiscal year  
22                   2021 and each subsequent fiscal year” and inserting  
23                   “each fiscal year”; and

24                   (3) in subsection (d)—

1 (A) by striking “2025” each place it ap-  
2 pears and inserting “2030”; and

3 (B) by adding at the end the following:

4 “(4) MINUTES OF NEGOTIATION MEETINGS.—

5 “(A) PUBLIC AVAILABILITY.—The Sec-  
6 retary shall make publicly available, on the pub-  
7 lic website of the Food and Drug Administra-  
8 tion, robust written minutes of all negotiation  
9 meetings conducted under this subsection be-  
10 tween the Food and Drug Administration and  
11 the regulated industry, not later than 30 days  
12 after each such negotiation meeting.

13 “(B) CONTENT.—The robust written min-  
14 utes described under subparagraph (A) shall  
15 contain, in detail, any substantive proposal  
16 made by any party to the negotiations as well  
17 as significant controversies or differences of  
18 opinion during the negotiations and their reso-  
19 lution.”.

20 (b) GAO REPORT.—

21 (1) IN GENERAL.—Not later than September  
22 30, 2027, the Comptroller General of the United  
23 States shall submit to the Committee on Health,  
24 Education, Labor, and Pensions of the Senate and  
25 the Committee on Energy and Commerce of the

1 House of Representatives a report assessing the sup-  
2 ply chain of over-the-counter monograph drugs.

3 (2) CONTENTS.—The report required under  
4 paragraph (1) shall include an assessment of—

5 (A) the overall stability of the supply chain  
6 of over-the-counter monograph drugs;

7 (B) what information is collected by the  
8 Food and Drug Administration with respect to  
9 the supply chain of over-the-counter monograph  
10 drugs;

11 (C) how the Food and Drug Administra-  
12 tion uses information collected on the supply  
13 chain of over-the-counter monograph drugs to  
14 inform regulatory decisions;

15 (D) how the Food and Drug Administra-  
16 tion coordinates with other Federal agencies to  
17 monitor and mitigate disruptions to the supply  
18 chain of over-the-counter monograph drugs; and

19 (E) the unique characteristics of the over-  
20 the-counter monograph drug marketplace and  
21 what additional authorities or information the  
22 Food and Drug Administration may need to en-  
23 sure the stability of the supply chain of over-  
24 the-counter monograph drugs.

1 **SEC. 506. TREATMENT OF ACTIVE INGREDIENTS FOR TOP-**  
2 **ICAL ADMINISTRATION.**

3 (a) IN GENERAL.—Section 505G of the Federal  
4 Food, Drug, and Cosmetic Act (21 U.S.C. 355h) is  
5 amended by adding at the end the following:

6 “(r) EVIDENCE AND TESTING STANDARDS FOR AC-  
7 TIVE INGREDIENTS FOR TOPICAL ADMINISTRATION.—

8 “(1) EVIDENCE AND TESTING STANDARDS FOR  
9 ACTIVE INGREDIENTS FOR TOPICAL ADMINISTRA-  
10 TION.—The Secretary shall—

11 “(A) in evaluating the generally recognized  
12 as safe and effective status of active ingredients  
13 used in nonprescription drugs intended for top-  
14 ical administration for purposes of subsection  
15 (a), utilize standards that allow for the use of  
16 real world evidence (as defined in section  
17 505F(b)), as appropriate, as part of a com-  
18 prehensive evaluation of scientific evidence to  
19 demonstrate the safety and effectiveness of such  
20 active ingredients, to supplement evidence from  
21 traditional clinical trials, provided that such  
22 standards allow the Secretary to evaluate  
23 whether the benefits of such active ingredients  
24 outweigh the risks; and

1           “(B) apply subsection (b)(6)(C) to the reg-  
2           ulation of active ingredients used in drugs in-  
3           tended for topical administration.

4           “(2) NON-ANIMAL TESTING METHODS FOR TOP-  
5           ICAL ACTIVE INGREDIENTS.—

6           “(A) IN GENERAL.—The Secretary shall  
7           consider the types of nonclinical tests described  
8           in paragraphs (1) through (4) of the first sub-  
9           section (z) of section 505 (as inserted by sec-  
10          tion 3209(a)(2) of the Health Extenders, Im-  
11          proving Access to Medicare, Medicaid, and  
12          CHIP, and Strengthening Public Health Act of  
13          2022 (division FF of Public Law 117–328)), or  
14          any other alternative to animal testing that the  
15          Secretary determines appropriate, in the consid-  
16          eration of drugs intended for topical adminis-  
17          tration under this section.

18          “(B) GUIDANCE.—Not later than 1 year  
19          after the date of enactment of this subsection,  
20          the Secretary shall issue new draft guidance on  
21          how sponsors can use nonclinical testing alter-  
22          natives to animal testing, as appropriate, to  
23          meet safety and efficacy standards under this  
24          section for drugs intended for topical adminis-  
25          tration.

1           “(3) CLARIFICATION.—Nothing in this sub-  
2           section shall be construed to alter, supersede, or  
3           limit the standards for making determinations of  
4           whether a drug is generally recognized as safe and  
5           effective under section 201(p) or the standards set  
6           forth under section 505 for determining the safety  
7           and effectiveness of drugs.”.

8           (b) SUNSCREEN FINAL ADMINISTRATIVE ORDER.—  
9           A final administrative order on nonprescription sunscreen  
10          active ingredients issued under section 3854 of the  
11          Coronavirus Aid, Relief, and Economic Security Act (Pub-  
12          lic Law 116–136; 21 U.S.C. 360fff–3 note) shall—

13               (1) account for historical data regarding the  
14               safety of sunscreen active ingredients that have pre-  
15               viously been accepted for marketing in the United  
16               States;

17               (2) account for the role of broad spectrum sun-  
18               screens with a Sun Protection Factor of 15 or high-  
19               er in effective skin cancer prevention; and

20               (3) incorporate the evidence and testing stand-  
21               ards for sunscreen active ingredients detailed in sec-  
22               tion 505G(r) of the Federal Food, Drug, and Cos-  
23               metic Act (21 U.S.C. 355h) (as added by subsection  
24               (a)).

1 **SEC. 507. INCREASING THE CLARITY AND PREDICTABILITY**  
2 **OF THE PROCESS FOR DEVELOPING APPLI-**  
3 **CATIONS FOR RX-TO-NONPRESCRIPTION**  
4 **SWITCHES.**

5 (a) IN GENERAL.—Section 505(b) of the Federal  
6 Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) is  
7 amended by adding at the end the following:

8 “(7) RX-TO-NONPRESCRIPTION SWITCHES.—

9 “(A) MEETINGS.—Any person planning to  
10 submit an application for an Rx-to-nonprescrip-  
11 tion switch may submit to the Secretary a writ-  
12 ten request for a meeting, for purposes of devel-  
13 oping a plan for such application that addresses  
14 the potential risks to public health of such  
15 switch and the evidence necessary to support  
16 such application, including the design of any  
17 necessary studies, and the format and content  
18 of the planned application. The Secretary may  
19 grant such a meeting, as appropriate, consistent  
20 with established procedures for granting meet-  
21 ings with, and providing written responses to,  
22 applications under this section. Each such  
23 meeting shall be documented in meeting min-  
24 utes.

25 “(B) GUIDANCE.—

1           “(i) IN GENERAL.—Not later than 18  
2 months after the date of enactment of this  
3 paragraph, the Secretary shall issue guid-  
4 ance to increase the clarity and predict-  
5 ability of the process and standards for ap-  
6 proval of applications for nonprescription  
7 drugs under this section, including in the  
8 case of applications for an Rx-to-non-  
9 prescription switch, especially with respect  
10 to prescription drugs with well-established  
11 safety profiles for which an applicant may  
12 seek approval for nonprescription use.

13           “(ii) CONTENTS.—The guidance  
14 under clause (i) shall—

15           “(I) describe how published re-  
16 ports in medical literature, any pre-  
17 vious finding of safety or effectiveness  
18 for the drug under this section, the  
19 results of significant human experi-  
20 ence with the drug, unpublished stud-  
21 ies and other data, and other sources  
22 of information may be used to support  
23 an application for a nonprescription  
24 drug, including in the context of an

1 application for an Rx-to-nonprescrip-  
2 tion switch;

3 “(II) set forth procedures for  
4 sponsors to request meetings de-  
5 scribed in subparagraph (A) and doc-  
6 ument the recommendations made in  
7 such meetings;

8 “(III) describe evidentiary expec-  
9 tations to support approval of an ap-  
10 plication for a nonprescription drug,  
11 including in the context of an applica-  
12 tion for an Rx-to-nonprescription  
13 switch, including how sponsors can  
14 demonstrate that consumers can ap-  
15 propriately self-select and use the  
16 drug and comprehend the non-  
17 prescription drug label; and

18 “(IV) provide recommendations  
19 for how mechanisms, in addition to  
20 the required Drug Facts Label, such  
21 as mobile applications and decisions  
22 aids, can be incorporated into the in-  
23 formation submitted in support of an  
24 application for an Rx-to-nonprescrip-  
25 tion switch.

1           “(C) PLAN TO ENGAGE WITH STAKE-  
2           HOLDERS.—Not later than 1 year after the  
3           date of enactment of this paragraph, the Sec-  
4           retary shall develop and make publicly available  
5           on the website of the Food and Drug Adminis-  
6           tration a plan to engage stakeholders on steps  
7           and factors for application holders and other  
8           stakeholders to consider in identifying approved  
9           prescription drugs that may be promising can-  
10          didates for applications for an Rx-to-non-  
11          prescription switch.

12          “(D) DEFINITION.—For purposes of this  
13          paragraph, the term ‘Rx-to-nonprescription  
14          switch’ means the approval of an application, or  
15          supplemental application, as applicable, sub-  
16          mitted under this section by the holder of an  
17          approved application for a prescription drug  
18          seeking approval to market such drug as a non-  
19          prescription drug, including for—

20                 “(i) a full Rx-to-nonprescription  
21                 switch, under which a drug previously ap-  
22                 proved for prescription use only is—

23                         “(I) approved for nonprescription  
24                         use under the same conditions as ap-

1                   plied to the drug when approved for  
2                   prescription use; or

3                   “(II) approved for nonprescrip-  
4                   tion use subject to one or more addi-  
5                   tional conditions for nonprescription  
6                   use; and

7                   “(ii) a partial Rx-to-nonprescription  
8                   switch, under which the drug is approved  
9                   for nonprescription use only under certain  
10                  conditions described in the approved label-  
11                  ing, while the drug otherwise remains ap-  
12                  proved for prescription use only.

13                  “(E) RULE OF CONSTRUCTION.—Nothing  
14                  in this paragraph shall be construed to—

15                  “(i) supersede or modify the authority  
16                  of the Secretary under section 505G with  
17                  respect to the regulation of OTC mono-  
18                  graph drugs; or

19                  “(ii) authorize the disclosure by the  
20                  Secretary of confidential commercial infor-  
21                  mation or trade secrets.”.

22                  (b) GAO REPORT.—

23                  (1) IN GENERAL.—Not later than 1 year after  
24                  the date of enactment of this Act, the Comptroller  
25                  General of the United States shall submit to the

1 Committee on Health, Education, Labor, and Pen-  
2 sions of the Senate and the Committee on Energy  
3 and Commerce of the House of Representatives a re-  
4 port that evaluates—

5 (A) the number of applications for an Rx-  
6 to-nonprescription switch approved during the  
7 period beginning on October 1, 2022, and end-  
8 ing on the date of the report;

9 (B) the number of drugs for which an ap-  
10 plication for an Rx-to-nonprescription switch  
11 was approved during such period subject to an  
12 additional condition for nonprescription use;

13 (C) among the drugs for which an applica-  
14 tion for a full or partial Rx-to-nonprescription  
15 switch was approved during such period, the av-  
16 erage length of time from receipt by the Food  
17 and Drug Administration of the application to  
18 the approval of such application;

19 (D) the number of partial Rx-to-non-  
20 prescription switch applications approved dur-  
21 ing such period, and the number of applications  
22 for such a partial switch not approved;

23 (E) any barriers to timely and predictable  
24 review of applications for an Rx-to-nonprescrip-  
25 tion switch;

1 (F) engagement by the Food and Drug  
2 Administration with public stakeholders, includ-  
3 ing public meetings or additional activities to  
4 support review of applications for an Rx-to-non-  
5 prescription switch; and

6 (G) opportunities for collaboration between  
7 the Center for Drug Evaluation and Research  
8 and the Centers for Medicare & Medicaid Serv-  
9 ices for the purpose of analyzing health insur-  
10 ance claims data for commonly prescribed drugs  
11 that appear to be suitable for an Rx-to-non-  
12 prescription switch.

13 (2) DEFINITION.—In this subsection, the term  
14 “Rx-to-nonprescription switch” has the meaning  
15 given such term in paragraph (7) of section 505(b)  
16 of the Federal Food, Drug, and Cosmetic Act (21  
17 U.S.C. 244(b)), as added by subsection (a).

18 **SEC. 508. REGULATION OF CERTAIN NONPRESCRIPTION**  
19 **DRUGS THAT ARE MARKETED WITHOUT AN**  
20 **APPROVED DRUG APPLICATION.**

21 (a) DEVELOPMENT ADVICE TO SPONSORS OR RE-  
22 QUESTORS.—Section 505G(h) of the Federal Food, Drug,  
23 and Cosmetic Act (21 U.S.C. 355h(h)) is amended by  
24 striking “sponsors or requestors” and inserting “sponsors,

1 requestors, or organizations nominated by sponsors or re-  
2 questors to represent their interests in a proceeding”.

3 (b) TECHNICAL CORRECTION.—Section  
4 505G(b)(2)(A)(iv)(III) of the Federal Food, Drug, and  
5 Cosmetic Act (21 U.S.C. 355h(b)(2)(A)(iv)(III)) is  
6 amended by striking “requestors” and inserting “sponsors  
7 or requestors”.

8 **SEC. 509. SUNSET DATES.**

9 (a) AUTHORIZATION.—Sections 744L and 744M of  
10 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
11 379j–71; 379j–72) shall cease to be effective October 1,  
12 2030.

13 (b) REPORTING REQUIREMENTS.—Section 744N of  
14 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
15 379j–73) shall cease to be effective January 31, 2031.

16 **SEC. 510. EFFECTIVE DATE.**

17 The amendments made by this title shall take effect  
18 on October 1, 2025, or the date of the enactment of this  
19 Act, whichever is later, except that fees under part 10 of  
20 subchapter C of chapter VII of the Federal Food, Drug,  
21 and Cosmetic Act (21 U.S.C. 379j–71 et seq.) shall be  
22 assessed beginning October 1, 2025, regardless of the date  
23 of the enactment of this Act.

1 **SEC. 511. SAVINGS CLAUSE.**

2 Notwithstanding the amendments made by this title,  
3 part 10 of subchapter C of chapter VII of the Federal  
4 Food, Drug, and Cosmetic Act (21 U.S.C. 379j–71 et  
5 seq.), as in effect on the day before the date of enactment  
6 of this Act, shall continue to be in effect with respect to  
7 assessing and collecting any fee required by such part for  
8 a fiscal year prior to fiscal year 2026.

9 **TITLE VI—NO SURPRISES ACT**  
10 **IMPLEMENTATION**

11 **SEC. 601. EXTENDING AVAILABILITY OF FUNDING FOR NO**  
12 **SURPRISES ACT IMPLEMENTATION.**

13 Section 118(a) of division BB of the Consolidated  
14 Appropriations Act, 2021 (Public Law 116–260) is  
15 amended—

16 (1) by striking “otherwise appropriated, to the  
17 Secretary of Health and Human Services” and in-  
18 serting the following: “otherwise appropriated—

19 “(1) to the Secretary of Health and Human  
20 Services”;

21 (2) in paragraph (1), as so inserted, by striking  
22 “September 30, 2025.” and inserting “November  
23 21, 2025; and”;

24 (3) by adding at the end the following new  
25 paragraph:

1           “(2) to the Secretary of Health and Human  
2           Services, in addition to amounts otherwise appro-  
3           priated under paragraph (1), \$15,000,000 for the  
4           period beginning on October 1, 2025, and ending on  
5           November 21, 2025.”.

6           **DIVISION D—DEPARTMENT OF**  
7           **VETERANS AFFAIRS EXTENDERS**  
8           **TITLE I—HEALTH CARE**  
9           **MATTERS**

10       **SEC. 101. EXTENSION OF AUTHORITY FOR COLLECTION OF**  
11                       **COPAYMENTS FOR HOSPITAL CARE AND**  
12                       **NURSING HOME CARE.**

13           Section 1710(f)(2)(B) of title 38, United States  
14           Code, is amended by striking “September 30, 2025” and  
15           inserting “November 21, 2025”.

16       **SEC. 102. EXTENSION OF REQUIREMENT TO PROVIDE**  
17                       **NURSING HOME CARE TO CERTAIN VET-**  
18                       **ERANS WITH SERVICE-CONNECTED DISABIL-**  
19                       **ITIES.**

20           Section 1710A(d) of title 38, United States Code, is  
21           amended by striking “September 30, 2025” and inserting  
22           “November 21, 2025”.

1 **SEC. 103. EXTENSION OF STAFF SERGEANT PARKER GOR-**  
2 **DON FOX SUICIDE PREVENTION GRANT PRO-**  
3 **GRAM.**

4 Section 201(j) of the Commander John Scott  
5 Hannon Veterans Mental Health Care Improvement Act  
6 of 2019 (Public Law 116–171; 38 U.S.C. 1720F note)  
7 is amended by striking “the date that is three years after  
8 the date on which the first grant is awarded under this  
9 section” and inserting “November 21, 2025”.

10 **SEC. 104. EXTENSION OF FUNDING FOR EXPANSION OF**  
11 **RURAL ACCESS NETWORK FOR GROWTH EN-**  
12 **HANCEMENT PROGRAM.**

13 Section 2(d) of the Sgt. Ketchum Rural Veterans  
14 Mental Health Act of 2021 (Public Law 117–21; 38  
15 U.S.C. 1712A note) is amended by striking “2025” and  
16 inserting “2026”.

17 **TITLE II—BENEFITS**

18 **SEC. 201. EXTENSION OF REQUIREMENT FOR QUARTERLY**  
19 **BRIEFINGS ON ADMINISTRATION OF AU-**  
20 **THORITIES RELATING TO DETERMINATIONS**  
21 **REGARDING PRESUMPTIONS OF SERVICE**  
22 **CONNECTION BASED ON TOXIC EXPOSURE.**

23 Section 202(b)(2) of the Sergeant First Class Heath  
24 Robinson Honoring our Promise to Address Comprehen-  
25 sive Toxics Act of 2022 (Public Law 117–168) is amended  
26 by striking “On a quarterly basis during the two-year pe-

1 rioid beginning on the date of the enactment of this Act,”  
2 and inserting “On a quarterly basis during the period be-  
3 ginning on the date of the enactment of this Act and end-  
4 ing on December 31, 2026,”.

5 **SEC. 202. EXTENSION OF REQUIREMENT RELATING TO RES-**  
6 **TORATION OF ENTITLEMENT TO EDU-**  
7 **CATIONAL ASSISTANCE IN CASES OF CLO-**  
8 **SURE OR DISAPPROVAL OF EDUCATIONAL IN-**  
9 **STITUTIONS.**

10 Section 3699(c)(2)(C) of title 38, United States  
11 Code, is amended by striking “September 30, 2025” and  
12 inserting “November 21, 2025”.

13 **SEC. 203. EXTENSION OF TEMPORARY CLARIFICATION OF**  
14 **LICENSURE REQUIREMENTS FOR CON-**  
15 **TRACTOR MEDICAL PROFESSIONALS TO PER-**  
16 **FORM MEDICAL DISABILITY EXAMINATIONS**  
17 **FOR THE DEPARTMENT OF VETERANS AF-**  
18 **FAIRS UNDER PILOT PROGRAM FOR USE OF**  
19 **CONTRACT PHYSICIANS FOR DISABILITY EX-**  
20 **AMINATIONS.**

21 Section 2002(a)(4) of the Johnny Isakson and David  
22 P. Roe, M.D. Veterans Health Care and Benefits Improve-  
23 ment Act of 2020 (Public Law 116–315; 38 U.S.C. 5101  
24 note) is amended by striking “five years” and inserting  
25 “six years”.



1 **SEC. 303. EXTENSION OF FUNDING FOR FINANCIAL ASSIST-**  
2 **ANCE FOR SUPPORTIVE SERVICES FOR VERY**  
3 **LOW-INCOME VETERAN FAMILIES IN PERMA-**  
4 **NENT HOUSING.**

5 Of the amounts appropriated to the Department of  
6 Veterans Affairs for fiscal year 2026 for “Medical Serv-  
7 ices”, \$92,000,000 shall be available until November 21,  
8 2025, to carry out subsections (a), (b), and (c) of section  
9 2044 of title 38, United States Code.

10 **SEC. 304. EXTENSION OF FUNDING FOR GRANT PROGRAM**  
11 **FOR HOMELESS VETERANS WITH SPECIAL**  
12 **NEEDS.**

13 Of the amounts appropriated to the Department of  
14 Veterans Affairs for fiscal year 2026 for “Medical Serv-  
15 ices”, \$833,333 shall be available until November 21,  
16 2025, for the purposes of the program under section 2061  
17 of title 38, United States Code.

18 **SEC. 305. EXTENSION OF AUTHORITY TO PROVIDE ASSIST-**  
19 **ANCE FOR SPECIALLY ADAPTED HOUSING**  
20 **FOR DISABLED VETERANS RESIDING TEMPO-**  
21 **RARILY IN HOUSING OWNED BY A FAMILY**  
22 **MEMBER.**

23 Section 2102A(e) of title 38, United States Code, is  
24 amended by striking “September 30, 2025” and inserting  
25 “November 21, 2025”.

1 **SEC. 306. EXTENSION OF AUTHORITY FOR SPECIALLY**  
2 **ADAPTED HOUSING ASSISTIVE TECHNOLOGY**  
3 **GRANT PROGRAM.**

4 Section 2108(g) of title 38, United States Code, is  
5 amended by striking “September 30, 2025” and inserting  
6 “November 21, 2025”.

7 **SEC. 307. IMPROVEMENTS TO PARTIAL CLAIM PROGRAM**  
8 **OF THE DEPARTMENT OF VETERANS AF-**  
9 **FAIRS.**

10 (a) **CLARIFICATION OF RELATIONSHIP TO OTHER**  
11 **POWERS OF SECRETARY.**—Section 3720(h) of title 38,  
12 United States Code, is amended by striking “of subsection  
13 (a)” and all that follows through the period at the end  
14 and inserting “of subsection (a) in conjunction with the  
15 purchase of a loan under section 3732(a)(2) of this title  
16 unless the Secretary determines the purchase would be  
17 made consistent with section 3732(d) of this title.”.

18 (b) **ADMINISTRATION OF PARTIAL CLAIM PRO-**  
19 **GRAM.**—Section 3737 of such title is amended—

20 (1) in subsection (b)(2), by striking “first lien  
21 guaranteed loan for such property” and inserting  
22 “amount of indebtedness under the guaranteed loan  
23 that the Secretary does not purchase”; and

24 (2) in subsection (c)—

25 (A) in paragraph (2)(B)(ii), by striking  
26 “120 days” and inserting “180 days”; and

1 (B) by amending paragraph (3) to read as  
2 follows:

3 “(3) An amount paid to the holder of a loan as a  
4 partial claim—

5 “(A) shall not alter the guaranty calculation  
6 specified by section 3703 of this title;

7 “(B) shall be included, for the purpose of a liq-  
8 uidation sale, in the same manner as any other ad-  
9 vance allowed by the Secretary; and

10 “(C) shall not be claimed under the guaranty or  
11 increase the Secretary’s cost of acquisition of the  
12 property securing the defaulted loan.”.

13 (c) REQUIREMENTS OF LOAN HOLDER.—Section  
14 (d)(1) of such section is amending by inserting “and serv-  
15 icing the loan” after “documents”.

16 (d) DEFAULT AND FORECLOSURE.—Subsection (e)  
17 of such section is amended—

18 (1) in paragraph (1)—

19 (A) in subparagraph (A), by striking “an  
20 individual who” and all that follows through the  
21 period at the end and inserting the following:

22 “a borrower who defaults on a partial claim  
23 shall be liable to the Secretary for any loss suf-  
24 fered by the Secretary with respect to such de-  
25 fault, and such loss may be recovered in the

1 same manner as any other debt due the United  
2 States. The Secretary shall not restore housing  
3 loan entitlement under section 3702(b) of this  
4 title until such loss is repaid in full.”; and

5 (B) by amending subparagraph (B) to read  
6 as follows:

7 “(B) The Secretary may charge administrative costs,  
8 fees, and interest, as appropriate, with respect to any de-  
9 fault under a partial claim in a manner similar to the in-  
10 terest and administrative costs charged under section  
11 5315 of this title.”; and

12 (2) by amending paragraph (2) to read as fol-  
13 lows:

14 “(2) Notwithstanding section 2410 of title 28, a non-  
15 judicial sale of real property to satisfy a loan guaranteed  
16 under this chapter shall discharge the property from a  
17 partial claim interest held by the Secretary, provided that  
18 the holder of the guaranteed loan conducts the non-judi-  
19 cial sale and distributes the sale proceeds, if any, in ac-  
20 cordance with the State or local law where such property  
21 is situated.”.

22 (e) GUIDANCE IN ADVANCE OF REGULATIONS.—Sub-  
23 section (h) of such section is amended to read as follows:

24 “(h) GUIDANCE IN ADVANCE OF REGULATIONS.—  
25 Notwithstanding any other provision of law, the Secretary

1 may, before prescribing regulations, issue administrative  
2 guidance with respect to the Partial Claim Program under  
3 this section and the loss mitigation options prescribed  
4 under section 3732(d) of this title, including any addi-  
5 tional terms, conditions, and requirements the Secretary  
6 determines necessary.”.

7 **SEC. 308. GOVERNMENT ACCOUNTABILITY OFFICE RE-**  
8 **PORTS ON PARTIAL CLAIM PROGRAM OF THE**  
9 **DEPARTMENT OF VETERANS AFFAIRS AND**  
10 **OTHER MATTERS.**

11 (a) ANNUAL REPORTS.—

12 (1) IN GENERAL.—Not later than one year  
13 after the date of the enactment of this Act, and  
14 every year thereafter until the Partial Claim Pro-  
15 gram terminates, the Comptroller General of the  
16 United States shall submit to the Committee on Vet-  
17 erans’ Affairs of the Senate and the Committee on  
18 Veterans’ Affairs of the House of Representatives a  
19 report.

20 (2) ELEMENTS.—Each report required by para-  
21 graph (1) shall include, for the period covered by the  
22 report and disaggregated by quarter, the following:

23 (A) Key data on the performance of the  
24 Partial Claim Program, including—

1 (i) the number of partial claims filed  
2 and approved; and

3 (ii) the redefault and foreclosure rates  
4 of loans for which a partial claim was  
5 made.

6 (B) A comparison of the data described in  
7 subparagraph (A) with data on the performance  
8 of other loss mitigation options provided by the  
9 Department of Veterans Affairs.

10 (C) The number of housing loans insured,  
11 guaranteed, or made by the Secretary of Vet-  
12 erans Affairs under chapter 37 of title 38,  
13 United States Code.

14 (D) The number of applications for hous-  
15 ing loan benefits under such chapter denied.

16 (E) The number of housing loans insured,  
17 guaranteed, or made by the Secretary under  
18 such chapter refinanced under section  
19 3710(a)(8) or 3712 of title 38, United States  
20 Code.

21 (F) The number of veterans who owe a  
22 payment on a mortgage associated with a loan  
23 insured, guaranteed, or made by the Secretary  
24 under such chapter that is at least—

25 (i) 60 days late; and

1 (ii) 90 days late.

2 (b) ASSESSMENT.—

3 (1) IN GENERAL.—Not later than one year be-  
4 fore the Partial Claim Program terminates, the  
5 Comptroller General shall—

6 (A) conduct an assessment of the benefits  
7 and challenges of the Partial Claim Program;  
8 and

9 (B) submit to the Committee on Veterans’  
10 Affairs of the Senate and the Committee on  
11 Veterans’ Affairs of the House of Representa-  
12 tives a report on the findings of the Comptroller  
13 General with respect to that assessment.

14 (2) CONSIDERATIONS.—In conducting the as-  
15 sessment required by paragraph (1), the Comptroller  
16 General shall consider the following:

17 (A) The characteristics of borrowers for  
18 whom a partial claim was made compared to  
19 the characteristics of borrowers provided other  
20 loss mitigation options by the Department of  
21 Veterans Affairs.

22 (B) The performance of loans guaranteed  
23 under chapter 37 of title 38, United States  
24 Code, following various loss mitigation actions.

1           (C) The information the Department con-  
2 sidered in determining whether a borrower  
3 would benefit from a partial claim compared to  
4 other loss mitigation options.

5           (D) The costs to taxpayers of the Partial  
6 Claim Program compared to the costs of other  
7 loss mitigation options provided by the Depart-  
8 ment.

9           (E) Any similarities and differences in the  
10 Department's administration and use of the  
11 Partial Claim Program compared to the De-  
12 partment's administration and use of the  
13 COVID-19 Veterans Assistance Partial Claim  
14 Payment program established under subpart F  
15 of part 36 of title 38, Code of Regulations.

16           (F) The information the Department  
17 learned from the COVID-19 Veterans Assist-  
18 ance Partial Claim Payment program and the  
19 extent to which those lessons learned were ap-  
20 plied to the Partial Claim Program.

21           (G) The types of information the Depart-  
22 ment collected to monitor the performance and  
23 effectiveness of the Partial Claim Program and  
24 how the Department used that information to  
25 make any needed adjustments to the program.

1           (H) How the use by the Department of  
2 partial claims compares to the use of partial  
3 claims by other Federal housing agencies, in-  
4 cluding, for each partial claim program—

5           (i) the volume of loans for which par-  
6 tial claims have been made;

7           (ii) the results for borrowers (includ-  
8 ing redefault and foreclosure rates); and

9           (iii) the costs to taxpayers.

10       (c) PARTIAL CLAIM PROGRAM DEFINED.—In this  
11 section, the term “Partial Claim Program” means the  
12 Partial Claim Program of the Department of Veterans Af-  
13 fairs carried out under section 3737 of title 38, United  
14 States Code.

## 15       **TITLE IV—OTHER MATTERS**

### 16       **SEC. 401. EXTENSION OF SUBPOENA AUTHORITY OF IN-** 17                               **SPECTOR GENERAL OF DEPARTMENT OF** 18                               **VETERANS AFFAIRS.**

19       Section 312(d)(7)(A) of title 38, United States Code,  
20 is amended by striking “September 30, 2025” and insert-  
21 ing “November 21, 2025”.

1 **SEC. 402. EXTENSION OF AUTHORITY FOR SECRETARY OF**  
2 **VETERANS AFFAIRS TO TRANSPORT INDIVID-**  
3 **UALS TO AND FROM FACILITIES OF DEPART-**  
4 **MENT OF VETERANS AFFAIRS.**

5 Section 111A(a)(2) of title 38, United States Code,  
6 is amended by striking “September 30, 2025” and insert-  
7 ing “November 21, 2025”.

8 **SEC. 403. EXTENSION OF AUTHORITY RELATING TO VEND-**  
9 **EE LOAN PROGRAM.**

10 Section 3733(a)(8) of title 38, United States Code,  
11 is amended—

12 (1) in the matter preceding subparagraph (A),  
13 by striking “September 30, 2025” and inserting  
14 “November 21, 2025”; and

15 (2) in subparagraph (C), by striking “Sep-  
16 tember 30, 2025” and inserting “November 21,  
17 2025”.

18 **SEC. 404. EXTENSION OF AUTHORITY FOR TRANSFER OF**  
19 **REAL PROPERTY.**

20 Section 8118(a)(5) of title 38, United States Code,  
21 is amended by striking “September 30, 2025” and insert-  
22 ing “November 21, 2025”.

23 **DIVISION E—MISCELLANEOUS**

24 **SEC. 101. BUDGETARY EFFECTS.**

25 (a) STATUTORY PAYGO SCORECARDS.—The budg-  
26 etary effects of divisions B through D shall not be entered

1 on either PAYGO scorecard maintained pursuant to sec-  
2 tion 4(d) of the Statutory Pay-As-You-Go Act of 2010.

3 (b) SENATE PAYGO SCORECARDS.—The budgetary  
4 effects of divisions B through D shall not be entered on  
5 any PAYGO scorecard maintained for purposes of section  
6 4106 of H. Con. Res. 71 (115th Congress).

7 (c) CLASSIFICATION OF BUDGETARY EFFECTS.—  
8 Notwithstanding Rule 3 of the Budget Scorekeeping  
9 Guidelines set forth in the joint explanatory statement of  
10 the committee of conference accompanying Conference Re-  
11 port 105–217 and section 250(c)(8) of the Balanced  
12 Budget and Emergency Deficit Control Act of 1985, the  
13 budgetary effects of divisions B through D shall not be  
14 estimated—

15 (1) for purposes of section 251 of such Act;

16 (2) for purposes of an allocation to the Com-  
17 mittee on Appropriations pursuant to section 302(a)  
18 of the Congressional Budget Act of 1974; and

19 (3) for purposes of paragraph (4)(C) of section  
20 3 of the Statutory Pay-As-You-Go Act of 2010 as  
21 being included in an appropriation Act.

Passed the House of Representatives September 19,  
2025.

Attest:

KEVIN F. MCCUMBER,

*Clerk.*

Calendar No. 168

119<sup>TH</sup> CONGRESS  
1<sup>ST</sup> Session

**H. R. 5371**

---

---

**AN ACT**

Making continuing appropriations and extensions  
for fiscal year 2026, and for other purposes.

---

---

SEPTEMBER 19 (legislative day, SEPTEMBER 16), 2025  
Received, read twice and ordered placed on the calendar